var title_f31_41_32400="Algorithm vaginal bleeding";
var content_f31_41_32400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Algorithm vaginal bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 599px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * This step may be omitted in women who are known to have an intrauterine pregnancy. Proceed directly to ultrasound examination.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32400=[""].join("\n");
var outline_f31_41_32400=null;
var title_f31_41_32401="First trimester ultrasound image of umbilical cord";
var content_f31_41_32401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    First trimester ultrasound image of umbilical cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Three-dimensional rendered image of a first-trimester fetus and its umbilical cord. Both the placental and abdominal insertion sites are shown. Note that the umbilical cord length at this gestational age is approximately the same as the crown rump length.",
"    <br>",
"     (Panel B) Transvaginal two-dimensional ultrasound shows a transverse view of the fetal abdomen (a), the entire length of the umbilical cord (uc) including its placental and fetal insertion sites, and the physiologic midgut herniation (arrow) at the base of the fetal insertion site.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32401=[""].join("\n");
var outline_f31_41_32401=null;
var title_f31_41_32402="Large tonsils";
var content_f31_41_32402=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large tonsils",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large tonsils often accompany obstructive sleep apnea in children. This photograph shows tonsils that would be graded as 4+ (\"kissing\") and could easily cause airway obstruction during sleep.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Ron Mitchell.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32402=[""].join("\n");
var outline_f31_41_32402=null;
var title_f31_41_32403="Folic acid, cyanocobalamin, and pyridoxine: Drug information";
var content_f31_41_32403=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Folic acid, cyanocobalamin, and pyridoxine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/16/260?source=see_link\">",
"    see \"Folic acid, cyanocobalamin, and pyridoxine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      FaBB;",
"     </li>",
"     <li>",
"      Folastin;",
"     </li>",
"     <li>",
"      Folbee&reg;;",
"     </li>",
"     <li>",
"      Folbic&trade;;",
"     </li>",
"     <li>",
"      Folcaps&trade;;",
"     </li>",
"     <li>",
"      Folgard RX&reg;;",
"     </li>",
"     <li>",
"      Folgard&reg; [OTC] [DSC];",
"     </li>",
"     <li>",
"      Folplex 2.2;",
"     </li>",
"     <li>",
"      Foltabs&trade; 800 [OTC];",
"     </li>",
"     <li>",
"      Foltx&reg; [DSC];",
"     </li>",
"     <li>",
"      Homocysteine Guard [OTC];",
"     </li>",
"     <li>",
"      Lev-Tov [OTC];",
"     </li>",
"     <li>",
"      Tri-B&reg; [OTC];",
"     </li>",
"     <li>",
"      Tricardio B;",
"     </li>",
"     <li>",
"      Virt-Vite Forte;",
"     </li>",
"     <li>",
"      Vita-Respa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F173856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F173849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement: Oral: One tablet daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F173850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Folic acid 0.8 mg, cyanocobalamin 100 mcg, and pyridoxine hydrochloride 50 mg; Folic acid 0.8 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 50 mg; Folic acid 2.2 mg, cyanocobalamin 500 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FaBB: Folic acid 2.2 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Folastin: Folic acid 2.5 mg, cyanocobalamin 2000 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Folbee&reg;: Folic acid 2.5 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg [dye free, lactose free, and sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Folbic&trade;: Folic acid 2.5 mg, cyanocobalamin 2000 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Folcaps&trade;: Folic acid 2.2 mg, cyanocobalamin 500 mcg, and pyridoxine hydrochloride 25 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Folgard&reg;: Folic acid 0.8 mg, cyanocobalamin 115 mcg, and pyridoxine hydrochloride 10 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Folgard RX&reg;: Folic acid 2.2 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Folplex 2.2: Folic acid 2.2 mg, cyanocobalamin 500 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Foltabs&trade; 800: Folic acid 0.8 mg, cyanocobalamin 115 mcg, and pyridoxine hydrochloride 10 mg [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Foltx&reg;: Folic acid 2.5 mg, cyanocobalamin 2000 mcg, and pyridoxine hydrochloride 25 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Homocysteine Guard: Folic acid 0.8 mg, cyanocobalamin 400 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lev-Tov: Folic acid 0.8 mg, cyanocobalamin 250 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tri-B&reg;: Folic acid 0.8 mg, cyanocobalamin 400 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tricardio B: Folic acid 0.4 mg, cyanocobalamin 250 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Virt-Vite Forte: Folic acid 2.5 mg, cyanocobalamin 2000 mcg, and pyridoxine hydrochloride 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vita-Respa&reg;: Folic acid 2.2 mg, cyanocobalamin 1300 mcg, and pyridoxine hydrochloride 25 mg [dye free and sugar free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F173841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nutritional supplement in end-stage renal failure, dialysis, hyperhomocysteinemia, homocystinuria, malabsorption syndromes, dietary deficiencies",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F173854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F173843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to folic acid, cyanocobalamin, pyridoxine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F173834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F173837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: Pyridoxine may diminish the therapeutic effect of Altretamine. Specifically when altretamine is used in combination with Cisplatin the response duration may be diminished.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Pyridoxine may increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May diminish the therapeutic effect of Cyanocobalamin. The expected hematologic response for the treatment of anemia may be opposed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May decrease the serum concentration of Cyanocobalamin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Folic Acid may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Pyridoxine may increase the metabolism of Fosphenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May decrease the serum concentration of Folic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Pyridoxine may diminish the therapeutic effect of Levodopa.  Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Folic Acid may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Folic Acid may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Pyridoxine may increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Folic Acid may decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltitrexed: Folic Acid may diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F173845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Folbic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-25-2 mg (90): $82.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Folcaps Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.2-25-0.5 mg (100): $38.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Folgard RX Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.2-25-1 mg (100): $63.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Foltabs 800 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800-10-115 mcg-mg-mcg (60): $14.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (NuFol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-25-1 mg (90): $39.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vita-Respa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.2-25-1.3 mg (90): $70.50",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5549477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bedoyecta Pedi&aacute;trica (MX);",
"     </li>",
"     <li>",
"      Kiddi Pharmaton (MX);",
"     </li>",
"     <li>",
"      Vitaver&aacute;n F&oacute;lico (MX);",
"     </li>",
"     <li>",
"      Vytral (MX)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al, &ldquo;Secondary Prevention With Folic Acid: Effects on Clinical Outcomes,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 41(12):2105-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32403/abstract-text/12821232/pubmed\" id=\"12821232\" target=\"_blank\">",
"        12821232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schnyder G, Roffi M, Flammer Y, et al, &ldquo;Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      , and Vitamin B",
"      <sub>",
"       6",
"      </sub>",
"      on Clinical Outcome After Percutaneous Coronary Intervention: The Swiss Heart Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(8):973-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32403/abstract-text/12190367/pubmed\" id=\"12190367\" target=\"_blank\">",
"        12190367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8692 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32403=[""].join("\n");
var outline_f31_41_32403=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173848\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173856\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173849\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173850\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173840\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173831\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173841\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173854\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173843\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173834\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299359\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173837\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287243\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287244\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173845\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5549477\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8692\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8692|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/16/260?source=related_link\">",
"      Folic acid, cyanocobalamin, and pyridoxine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_41_32404="Olopatadine (nasal): Drug information";
var content_f31_41_32404=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Olopatadine (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/60/35779?source=see_link\">",
"    see \"Olopatadine (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9502825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Patanase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9502835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9502955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"     Intranasal: 2 sprays into each nostril twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9502954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"     Intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 6-11 years: 1 spray into each nostril twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9502956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9504100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patanase&reg;: 0.6% (30.5 g) [contains benzalkonium chloride; equivalent to olopatadine hydrochloride 665 mcg/100 microliters; 240 metered sprays]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9502828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9503378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     For intranasal use only. Before initial use of the nasal spray, the delivery system should be primed with 5 sprays or until a fine mist appears. If 7 or more days have elapsed since last use, the delivery system should be reprimed with 2 sprays or until a fine mist appears. Blow nose to clear nostrils. Keep head tilted downward when spraying. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Alternate sprays between nostrils. After each use, wipe the spray tip with a clean tissue or cloth.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9502868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Treatment of the symptoms of seasonal allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9502876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Bitter taste (13%; children 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis (3% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (2%), fatigue (1%), somnolence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (children 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Weight gain (1%), xerostomia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal ulceration (9% to 10%), upper respiratory tract infection (children 3%), pharyngolaryngeal pain (2%), postnasal drip (2%), cough (1%), throat irritation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anosmia, hyposmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9502872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9502873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause drowsiness in some patients; instruct patient to use caution when driving or operating machinery. Effects may be additive with CNS depressants and/or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nasal ulcerations: Periodically examine nasal mucosa for ulceration and consider discontinuing if ulceration occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9502880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9502884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9502869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9502870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Adverse effects were observed in animal reproduction studies when using doses greater than the equivalent maximum recommended human dose.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9502871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9504102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Patanase Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.6% (30.5 g): $185.46",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9503386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe patients periodically for adverse nasal effects (eg, ulceration, perforation).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9502928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective histamine H",
"     <sub>",
"      1",
"     </sub>",
"     -antagonist; inhibits release of histamine from mast cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9502930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Onset of action: 30 minutes in seasonal allergy patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Protein binding: ~55% (primarily albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Metabolism: Not extensively metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Bioavailability: 57%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Half-life elimination: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Time to peak, serum: 15 minutes to 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Excretion: Urine (60% to 70%, mostly as unchanged drug); feces (17%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9893 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32404=[""].join("\n");
var outline_f31_41_32404=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502825\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502835\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502955\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502954\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502956\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504100\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502828\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9503378\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502868\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502876\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502872\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502873\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299785\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502880\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502884\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502869\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502870\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502871\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504102\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9503386\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502928\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9502930\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9893\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9893|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/60/35779?source=related_link\">",
"      Olopatadine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/43/20147?source=related_link\">",
"      Olopatadine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/2/8228?source=related_link\">",
"      Olopatadine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_41_32405="Tinea corporis on trunk";
var content_f31_41_32405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea corporis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An inflammatory, annular plaque with peripheral scale is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32405=[""].join("\n");
var outline_f31_41_32405=null;
var title_f31_41_32406="Histology case 5";
var content_f31_41_32406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Histology case 5",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32406=[""].join("\n");
var outline_f31_41_32406=null;
var title_f31_41_32407="Joint protection program for the lower limb";
var content_f31_41_32407=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Joint protection program for the lower limb",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/41/32407/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32407/contributors\">",
"     Sharon Alzner, MPT",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32407/contributors\">",
"     Zacharia Isaac, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/41/32407/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32407/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/41/32407/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32407/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/41/32407/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every patient with a chronic joint disorder should be educated regarding the principles of joint protection, as excess stress and strain on arthritic joints can add to inflammation and degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/1\">",
"     1",
"    </a>",
"    ]. The goal of lower extremity joint protection is to avoid overloading vulnerable",
"    <span class=\"nowrap\">",
"     joints/tissues,",
"    </span>",
"    to prevent recurrent sprains and strains, to reduce pain and inflammation, and, thus, to preserve joint integrity.",
"   </p>",
"   <p>",
"    Joint protection is best achieved through patient education, behavior modification, energy conservation, and, in selected cases, use of orthotic devices, splints, adaptive devices, and, in the case of the lower extremities, proper footwear. Conservative care includes preventive care, and joint protection is a fundamental way to provide preventive joint care.",
"   </p>",
"   <p>",
"    Joint protection for the lower extremities will be reviewed here. An overview of joint protection and joint protection for the upper extremities and neck are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35896?source=see_link\">",
"     \"Overview of joint protection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37508?source=see_link\">",
"     \"Joint protection program for the upper limb\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30085?source=see_link\">",
"     \"Joint protection program for the neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF JOINT PROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of joint protection are derived from the simple, practical application of proper body mechanics, posture, and positioning of joints. Joint protection reduces local joint stress and preserves joint integrity. Guiding the patient to perform a task in a manner that puts less stress on joints is generally preferred to prohibiting the task [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principles of joint protection include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respect pain",
"     </li>",
"     <li>",
"      Reduce excess body weight",
"     </li>",
"     <li>",
"      Demonstrate proper posture and body mechanics",
"     </li>",
"     <li>",
"      Use minimum force for energy conservation and injury prevention",
"     </li>",
"     <li>",
"      Participate in regular exercise, as tolerated, to maintain function, range of motion, strength, and balance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These principals and their application are discussed in detail in the sections below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Respect pain",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is important for patients with any arthritic condition to understand that pain is usually an indicator that a particular activity is placing an excessive load on the joint; pain may thus be interpreted as a signal for the patient to modify or avoid the activity.",
"     </li>",
"     <li>",
"      Patients should warm up before doing exercises or vigorous activity. A warm up should consist of 5 to 10 minutes of gentle joint range of motion exercises or any gentle activity that increases the heart rate.",
"     </li>",
"     <li>",
"      We advise that patients should choose footwear with comfort, support, and utility in mind and that patients should not wear shoes that cause pain or fatigue. Individualized assessment is an important component of a joint protection intervention.",
"      <br/>",
"      <br/>",
"      The history of past shoe wear may be important for women with current foot pain. Women who wore &ldquo;good shoes,&rdquo; compared with women who wore &ldquo;average shoes,&rdquo; in the past were 67 percent less likely to report hindfoot pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/4\">",
"       4",
"      </a>",
"      ]. This study, using data from the Framingham (MA) study, defined &ldquo;good shoes&rdquo; as low-risk shoes, including athletic and casual sneakers with rigid heel counters, fixation, or firm, non-flexible soles. &ldquo;Average shoes&rdquo; included those with hard or rubber soles, special shoes, and work boots. &ldquo;Poor shoes&rdquo; included those that lack support and sound structure, including high-heeled shoes, sandals, and slippers.",
"      <br/>",
"      <br/>",
"      A systematic review found evidence that special shoes and orthoses may benefit patients with rheumatoid arthritis (RA) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/5\">",
"       5",
"      </a>",
"      ]. However, patient dissatisfaction with footwear often resulted in decreased usage, while participation in the design stage of specialized footwear improved usage, decreased pain, and improved foot health [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The following issues should be noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient acceptance of footwear is needed for clinical benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Appropriate shoes should provide support and comfort for the weight-bearing foot, with room for the toes to extend fully and to broaden out during weight-bearing. A certified pedorthist can construct custom shoes, with a doctor&rsquo;s prescription, for patients with structural foot deformities. In addition, orthotics may be obtained from a medical equipment company with the advice and assistance of a treating physical therapist or podiatrist. If a patient has a structural deformity that may require custom made orthotics, then it is advised that the patient pursue a podiatry consultation.",
"     </li>",
"     <li>",
"      Proper fit should be determined by having the foot size measured while standing.",
"     </li>",
"     <li>",
"      Attention should be given to wearing shoes with an appropriate heel height (usually a one-inch heel). They should fit the description of a \"good shoe,\" as specified above, and should be checked often for signs of wear.",
"     </li>",
"     <li>",
"      Cushion soles with shock absorbing material should be used if walking or working on concrete.",
"     </li>",
"     <li>",
"      Running shoes, walking shoes, or aerobics shoes are more supportive and comfortable to the flexible or arthritic foot. Good running shoes and arch supports are important.",
"     </li>",
"     <li>",
"      A metatarsal pad or bar can be used to relieve pressure or pain at the forefoot. A certified orthotist can make a custom fit orthotic with a metatarsal pad. A metatarsal pad helps unload the metatarsal heads, which can decrease pain at the forefoot. Metatarsal pads can be purchased over the counter or online; however, patients with special foot care needs or foot deformities may need to have a custom fit metatarsal pad made by an orthotist.",
"     </li>",
"     <li>",
"      Footwear that is especially designed for a particular sport should be used for participation in that activity.",
"     </li>",
"     <li>",
"      In patients who do not respond with a reduction in pain to the more simple measures described above, we recommend evaluation by a podiatrist.",
"     </li>",
"     <li>",
"      Orthoses can provide needed support and positioning assistance. We suggest consultation with an experienced professional regarding the choice of an orthosis, whether having it custom made or obtaining it over-the-counter. For patients with structural foot deformities, custom orthoses can be fit and made by a certified orthotist, physical therapist, podiatrist, or a certified pedorthist, with the appropriate prescription from a podiatrist (or physical therapist). Orthoses should then be used in both sports shoes and everyday shoes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no consensus on the choice of foot orthoses used for managing pathology in the rheumatoid foot, although there is strong evidence that foot orthoses do reduce pain and improve functional ability. The type of foot orthoses used range from simple cushioned insoles to custom-made rigid cast devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2008 systematic review [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/8\">",
"       8",
"      </a>",
"      ] found that, for people diagnosed with rheumatoid arthritis, custom-made foot orthoses, which can be made by a certified orthotist, pedorthist, or physical therapist with a prescription or by a podiatrist, are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      More effective than no intervention for reducing rear foot pain up to 30 months",
"     </li>",
"     <li>",
"      Not more effective than a standard intervention of supportive shoes or non-custom foot orthoses for reducing metatarsophalangeal (MTP) joint pain or for improving function after six weeks or three months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with joint",
"      <span class=\"nowrap\">",
"       hypermobility/laxity",
"      </span>",
"      should be particularly careful to protect the ankles and feet. Sprains and strains can increase joint instability.",
"     </li>",
"     <li>",
"      If synovitis or synovial effusion is present, joint aspiration and injection, where indicated clinically, can result in a more rapid response to physical therapy and joint protection principles.",
"     </li>",
"     <li>",
"      The weight-bearing load should be distributed over stronger joints",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      larger surface areas.",
"     </li>",
"     <li>",
"      Patients should avoid overloading the joints and should instead use the muscles that surround the joint. For example, the thigh muscles can be used to rise from a chair.",
"     </li>",
"     <li>",
"      Patients should avoid maintaining the same joint position for prolonged periods. Straightening the knees or standing up at least every 30 minutes during prolonged periods of sitting relieves pressure and stretches tight muscles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reduce excess body weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advise that patients maintain an appropriate weight to reduce stress on the knees, feet, and ankles. Increased body mass index is associated with onset and progression of osteoarthritis of the knee (but not the hip) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, the combination of modest weight loss plus moderate exercise provides improvements in overall pain and performance measures of mobility in older overweight obese adults with knee OA compared with either intervention alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29370?source=see_link&amp;anchor=H5#H5\">",
"     \"Risk factors for and possible causes of osteoarthritis\", section on 'Obesity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Posture and body mechanics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advise that patients use good posture and proper body mechanics. The following points should be reviewed with patients, depending upon their individual activities or symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hip and buttock region pain may result from bending at the waist while the knees are locked straight. Persons with joint laxity are more likely to bend improperly (",
"      <a class=\"graphic graphic_picture graphicRef75222 \" href=\"mobipreview.htm?17/40/18050\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When lifting heavy loads, it is better to bend at the knee and not at the waist and to avoid allowing both knees to pass over the toes. Lifting should be done with thigh muscles, straightening the knees first then the back (",
"      <a class=\"graphic graphic_picture graphicRef64062 \" href=\"mobipreview.htm?0/51/816\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the patient's job or task requires prolonged standing at one site, placing a 12-inch long 2X4 inch board on the floor, then placing one foot on and off of it at intervals, alternating feet, can reduce lower limb fatigue (",
"      <a class=\"graphic graphic_picture graphicRef56903 \" href=\"mobipreview.htm?26/33/27152\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Twisting should be avoided while carrying a heavy load, which should be held close to the body. It is better to move the body as a unit when carrying a heavy load to avoid excessive stress and strain on the low back, hips, knees, and ankles (",
"      <a class=\"graphic graphic_picture graphicRef74843 \" href=\"mobipreview.htm?33/24/34191\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef55361 \" href=\"mobipreview.htm?31/24/32143\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When lifting heavy objects, the load should be kept centered in front of the body. Carrying heavy items in one hand at the side of the body should be avoided (",
"      <a class=\"graphic graphic_picture graphicRef76812 \" href=\"mobipreview.htm?34/5/34911\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Knee pain can be caused by foot disorders; the entire lower leg should be evaluated when investigating this complaint.",
"     </li>",
"     <li>",
"      Patients should modify or avoid knee twisting dance steps or exercises.",
"     </li>",
"     <li>",
"      Patients should try to sit with lumbar support and with feet in contact with the ground. Sitting with a leg folded under or in a crossed-legged position should be avoided (",
"      <a class=\"graphic graphic_picture graphicRef70254 \" href=\"mobipreview.htm?36/13/37087\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The knee should not pass over the toes when squatting. This helps prevent placing excessive stress on the knee joint (",
"      <a class=\"graphic graphic_picture graphicRef54894 \" href=\"mobipreview.htm?25/49/26399\">",
"       picture 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      It is preferable to avoid loading the knee joint at angles greater than 45 degrees [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/11\">",
"       11",
"      </a>",
"      ]. For example, deep knee squats and squatting for prolonged periods of time should be avoided.",
"     </li>",
"     <li>",
"      Ergonomic",
"      <span class=\"nowrap\">",
"       assessments/interventions",
"      </span>",
"      are very useful in preventing work-related injuries and play an important role in joint protection. Results from a pilot study on an ergonomic assessment tool for arthritis (EATA) indicate that it is a feasible and a comprehensive process for identifying ergonomic job accommodations for patients with inflammatory arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Minimum force",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be advised to use the minimum amount of force necessary to complete the job. This not only protects the joints but also plays a role in energy conservation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proper footwear helps minimize force. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Respect pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Knee joint protection: Knee joint loading is an important factor in the progression of osteoarthritis (OA). Excessive medial joint loading of the knee occurs with a high adduction moment, which increases as the knee becomes more varus. Patients with a varus alignment demonstrate a higher incidence of medial compartment OA. Therefore, varus alignment is widely accepted as an indicator of the extent of medial compartment loading. A 1 percent increase in adduction moment increases the risk of OA progression by 6.46 times and is a useful research measure for evaluating treatment strategies designed to slow disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Valgus knee bracing: One conservative non-surgical intervention, which can reduce the adduction moment at the knee for patients with medial compartment OA, is the use of a valgus knee brace [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/14\">",
"       14",
"      </a>",
"      ]. Adjustable valgus bracing is effective in reducing medial compartment load and improved pain in a group of patients with knee OA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A gait analysis study with 40 subjects with medial knee OA found that wearing shoes increases medial knee joint load, compared with walking barefoot, and that the use of a cane significantly reduces medial knee loading [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/15\">",
"       15",
"      </a>",
"      ]. Off the shelf shoes predisposed knee osteoarthritis patients to excessive joint loading, and use of a cane had a protective effect on disease progression.",
"     </li>",
"     <li>",
"      Footwear for knee protection: Off the shelf and footwear recommendations for patients with medial compartment OA based upon current research include [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/16\">",
"       16",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Avoid shoes with medial arch supports.",
"     </li>",
"     <li>",
"      Wear shoes with heels 1.5 inches or less.",
"     </li>",
"     <li>",
"      Choose shoes with flexible soles in preference to supportive shoes promoting stability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mobility shoe, designed to simulate natural foot motion during barefoot walking, decreased joint loading compared with off the shelf footwear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To date, there is little research on the benefits of shock-absorbing insoles and textured insoles, though there is anecdotal evidence of benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of the lateral wedge for symptomatic benefit is widely recommended in guidelines for the treatment of knee OA. Current research supports the following recommendations for the lateral wedge for people with medial knee osteoarthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/16\">",
"       16",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wedge the full length of the foot, not just the heel.",
"     </li>",
"     <li>",
"      Wedge angle around 5 degrees; greater than 10 degrees is associated with discomfort.",
"     </li>",
"     <li>",
"      Use off the shelf shoe recommendations above.",
"     </li>",
"     <li>",
"      Wedges should immediately reduce pain for longer clinical benefits to be achieved.",
"     </li>",
"     <li>",
"      Better outcomes are observed with less severe disease, with increased lower limb muscle mass, in younger individuals, and in those who are less obese [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is preliminary evidence from small studies that flexible medial wedged insoles can be used for predominately lateral compartment OA. Further research is needed. Medial arch supports could be detrimental for individuals with medial compartment OA, so caution needs to be used in recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations to patients for knee protection include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use a mechanic's or milker's stool when working on the floor or on the ground. Sit with the legs apart and reach forward to perform tasks such as gardening or scrubbing floors.",
"     </li>",
"     <li>",
"      Use protective knee pads if you must work on hands and knees.",
"     </li>",
"     <li>",
"      In patients with chronic joint disorders or joint pain who are avid gardeners, raised bed or container-gardening are excellent options, as it is easy to garden on a stool, which reduces stress and effort on the body and joints.",
"     </li>",
"     <li>",
"      Avoid deep knee bending; use &ldquo;reacher&rdquo; tools for assistance. Simplify work by using efficiency principles: plan, organize, and balance work with rest.",
"     </li>",
"     <li>",
"      Run on dirt or track surfaces; avoid running on concrete or asphalt.",
"     </li>",
"     <li>",
"      Remain active to",
"      <span class=\"nowrap\">",
"       maintain/increase",
"      </span>",
"      strength and range of motion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8247850\">",
"    <span class=\"h2\">",
"     Regular exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular exercise helps to maintain function, joint range of motion, strength, and balance.",
"   </p>",
"   <p>",
"    A 2009 systematic review of 121 randomized trials, which examined the benefits of progressive resistance strength training (PRT) for improving physical function in older adults, found that PRT, performed two to three times a week at high intensity, improved physical ability, strength, gait, and performance of functional tasks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/18\">",
"     18",
"    </a>",
"    ]. Participants with OA reported a reduction in pain in five studies. Still, caution should be taken in generalizing from these results to clinical practice, as adverse events such as muscle pain and joint pain were poorly recorded in some of the studies.",
"   </p>",
"   <p>",
"    One essential component of preventative care for lower extremity joint protection is fall prevention. Evaluation of lower extremity strength and balance, typically as part of an interdisciplinary assessment, is an important component of effective fall prevention programs for older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Population-based fall prevention programs have been shown to be effective and can form the basis of public health practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    A 2007 systematic review of the benefits of exercise for improving balance in older people, involving 34 studies, found that balance significantly improved with exercise interventions compared with usual activity. Multiple types of exercise, including gait, balance, coordination, functional exercises, and muscle strength, appeared to have the greatest impact on balance. There was a trend toward improvement in balance from riding a stationary bike. However, based on these studies, there is limited evidence that effects were long lasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial involving 120 patients found benefit of increased self-efficacy in arthritis self-management education programs. Those in the treatment group had increased self efficacy for using cold and hot compresses, using two to three joint protection practices, and increased duration of light exercise. Increased perceived self-efficacy was associated with increased performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise advice for lower limb joint protection includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strengthening the thigh muscles",
"      <span class=\"nowrap\">",
"       (quadriceps/hamstrings)",
"      </span>",
"      to protect the knee. A home-based quadriceps exercise program improves symptomatic osteoarthritis of the knee to the same degree as NSAIDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise Guidelines: A review written to guide health professionals in exercise prescription for people with arthritis provided the following recommendations to the patient regarding aerobic exercise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/24\">",
"       24",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Include an adequate warm-up and cool-down phase to minimize risk of injury",
"     </li>",
"     <li>",
"      Allow for variations in disease activity and joint status",
"     </li>",
"     <li>",
"      Be safe, comfortable, and easy to perform",
"     </li>",
"     <li>",
"      Be enjoyable and promote exercise confidence",
"     </li>",
"     <li>",
"      Place minimal stress (impact, torsional, shearing forces) on the affected joint(s)",
"     </li>",
"     <li>",
"      Allow for correct posture and joint alignment",
"     </li>",
"     <li>",
"      Appropriate aerobic exercise should not cause pain or increase local disease activity during performance or immediately afterward.",
"     </li>",
"     <li>",
"      Use splints and recommended joint protection measures as medically indicated",
"     </li>",
"     <li>",
"      Avoid unwanted or deforming joint positions",
"     </li>",
"     <li>",
"      Exercise should not increase or lead to muscle imbalances about a joint.",
"     </li>",
"     <li>",
"      Desired or recommended exercise intensity and duration should be permitted.",
"     </li>",
"     <li>",
"      Exercise should be readily available, convenient, and inexpensive.",
"     </li>",
"     <li>",
"      Exercise can promote socialization and peer support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of the type of exercise recommended for people requiring lower limb joint protection can include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stationary biking:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stationary biking provides safe, low impact exercise (",
"      <a class=\"graphic graphic_picture graphicRef71844 \" href=\"mobipreview.htm?36/32/37391\">",
"       picture 9",
"      </a>",
"      ). The seat height should be adjusted so that the knees are slightly bent at the low point of the downstroke and are no more than 90 degrees flexed on the upstroke. Increase resistance gradually.",
"     </li>",
"     <li>",
"      In patients for whom an upright stationary bike is too difficult or uncomfortable, a recumbent bike can be an effective alternative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Walking:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Short brisk walks will increase leg circulation and exercise muscles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aquatic exercise:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Water is an excellent medium in which to exercise for anyone with a rheumatologic disorder. It is sometimes the only environment that allows for pain-free movement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A study in 2007 found that a six-week aquatic physical therapy program resulted in significantly less pain and improved physical function, strength, and quality of life for people with hip and knee arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following is also advised:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform a regular stretching program for the muscles of the upper and lower leg. Tight muscles can contribute to knee problems.",
"     </li>",
"     <li>",
"      Engage in exercise and sports activities on a regular basis rather than occasional weekend participation. Include warm-up and cool-down activities as well as appropriate stretching in your routine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Support for the benefits of exercise were shown in a trial to examine the effects of diet and exercise on pain and function in overweight patients with knee pain, in which 389 such patients, both men and women, were randomly assigned to a home-based program with one of four conditions: dietary intervention plus quadriceps strengthening, dietary intervention alone, quadriceps strengthening alone, and advice leaflet only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/26\">",
"     26",
"    </a>",
"    ]. At 24 months, those in exercise interventions had a significantly greater frequency of achieving a moderate reduction in knee pain and improved knee function compared with those in the other groups. While moderate sustained weight loss was achieved with dietary intervention and was associated with decreased depression, there was no apparent impact on pain or function.",
"   </p>",
"   <p>",
"    It is important to note that people having an active rheumatoid arthritis (RA) flare can engage in an exercise program, as tolerated. One study found that moderate- or high-intensity weight-bearing exercises are safe with respect to disease activity and radiologic damage of hands and feet; however, caution should be taken when prescribing long-term high-intensity weight-bearing exercises to patients who have significant radiologic damage to larger joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In addition, a short-term intensive exercise program in active RA patients was shown to be more effective in improving muscle strength than a conservative exercise program and did not have any negative effects on disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32407/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RESOURCES FOR TASK-RELATED PAIN (OCCUPATIONAL INJURIES)",
"    </span>",
"   </p>",
"   <p>",
"    For patients:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.sjhc.london.on.ca/sjh/programs/arthritic/general/tips.htm\">",
"     www.sjhc.london.on.ca/sjh/programs/arthritic/general/tips.htm",
"    </a>",
"   </p>",
"   <p>",
"    St. Joseph's Hospital London, Ontario, Canada",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.webmd.com/\">",
"     www.webmd.com",
"    </a>",
"   </p>",
"   <p>",
"    Provides general information including: Ask the Expert, Medical Library, Message Boards &amp; More",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/index.asp\">",
"     www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/index.asp",
"    </a>",
"   </p>",
"   <p>",
"    Written by rheumatologists",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.ncfh.org/index.php?pid=113\">",
"     file://www.ncfh.org/index.php?pid=113",
"    </a>",
"   </p>",
"   <p>",
"    Ergonomics for farm workers",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://orthopedics.about.com/\">",
"     file://orthopedics.about.com/",
"    </a>",
"   </p>",
"   <p>",
"    Written by orthopaedists",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.ccohs.ca/\">",
"     www.ccohs.ca",
"    </a>",
"   </p>",
"   <p>",
"    Canadian Centre for Occupational Health and Safety",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.sammonspreston.com/\">",
"     www.sammonspreston.com",
"    </a>",
"   </p>",
"   <p>",
"    A catalog of energy saving devices, adapted ADL equipment and splints",
"   </p>",
"   <p>",
"    For physicians:",
"   </p>",
"   <p>",
"    Human Factors and Ergonomics Society",
"   </p>",
"   <p>",
"    Box 1369",
"   </p>",
"   <p>",
"    Santa Monica, CA 90406",
"   </p>",
"   <p>",
"    310-394-1811",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://www.hfes.org/web/SiteSearch.aspx?scope=publications&amp;search=Type+search+words+here&amp;Go.x=12&amp;Go.y=3\">",
"     file://www.hfes.org/web/SiteSearch.aspx?scope=publications&amp;search=Type+search+words+here&amp;Go.x=12&amp;Go.y=3",
"    </a>",
"   </p>",
"   <p>",
"    Applied Ergonomics (journal)",
"   </p>",
"   <p>",
"    Elsevier Science Ltd.",
"   </p>",
"   <p>",
"    Langford Lane",
"   </p>",
"   <p>",
"    Kidlington",
"   </p>",
"   <p>",
"    Oxford,OX5 1GB,UK",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://www.elsevier.com/locate/apergo\">",
"     www.elsevier.com/locate/apergo",
"    </a>",
"   </p>",
"   <p>",
"    U. Department of Health and Human Services",
"   </p>",
"   <p>",
"    4676 Columbia Pkwy",
"   </p>",
"   <p>",
"    Cincinnati, OH 45226",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://www.hhs.gov/\">",
"     www.hhs.gov",
"    </a>",
"   </p>",
"   <p>",
"    American Industrial Hygiene Assn",
"   </p>",
"   <p>",
"    2700 Prosperity Ave, Ste 250",
"   </p>",
"   <p>",
"    Fairfax, VA 22031",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://www.aiha.org/\">",
"     www.aiha.org",
"    </a>",
"   </p>",
"   <p>",
"    Job Accommodation Network",
"   </p>",
"   <p>",
"    809 Allen Hall",
"   </p>",
"   <p>",
"    PO Box 6123",
"   </p>",
"   <p>",
"    West Virginia University",
"   </p>",
"   <p>",
"    Morgantown, WV 26506-6123",
"   </p>",
"   <p>",
"    800-526-7234",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://janweb.icdi.wvu.edu/\">",
"     janweb.icdi.wvu.edu",
"    </a>",
"   </p>",
"   <p>",
"    Ergonomic tools for workers:",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     file://www.alimed.com/ergonomics/industrial-ergonomics/default.aspx",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18569439\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with chronic joint disorders should be educated regarding the principles of joint protection, as excess strain on arthritis joints can worsen inflammation and joint injury. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principles of joint protection are derived from the simple, practical application of proper body mechanics, posture, and positioning of joints. Guiding the patient to perform a task in a manner that puts less stress on joints is generally preferred to prohibiting the task. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Principles of joint protection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important for patients with any arthritic condition to understand that pain is usually an indicator that a particular activity is placing an excessive load on the joint; pain may thus be interpreted as a signal for the patient to modify or avoid the activity. Patients should warm up before doing exercises or vigorous activity. We advise that patients should choose footwear with comfort, support, and utility in mind and that patients should not wear shoes that cause pain or fatigue. Individualized assessment is an important component of a joint protection intervention. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Respect pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We advise that patients maintain an appropriate weight to reduce stress on the knees, feet, and ankles. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Reduce excess body weight'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We advise that patients use good posture and proper body mechanics. These points should be reviewed with patients and should be individualized depending upon their particular activities or symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Posture and body mechanics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient should be advised to use the minimum amount of force necessary to complete the job. This not only protects the joints but also plays a role in energy conservation. Specific strategies should be individualized to the patients&rsquo; activities and needs. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Minimum force'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regular exercise is recommended to help maintain function, joint range of motion, strength, and balance. Patients requiring lower limb joint protection may benefit from exercises such as stationary biking, walking, or aquatic exercise and should participate in exercise activities on a regular rather than occasional basis. (See",
"      <a class=\"local\" href=\"#H8247850\">",
"       'Regular exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple resources are available to assist both patients and clinicians in strategies for joint protection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Resources for task-related pain (occupational injuries)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sheon RP, Orr PM. Appendix B. A Joint protection guide for rheumatic disorders. In: Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, Third Edition, Sheon RP, Moskowitz RW, Goldberg VM (Eds), Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/2\">",
"      Barlow JH, Turner AP, Wright CC. A randomized controlled study of the Arthritis Self-Management Programme in the UK. Health Educ Res 2000; 15:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/3\">",
"      Streibelt M, Hansmeier T, M&uuml;ller-Fahrnow W. [Effects of work-related medical rehabilitation in patients with musculoskeletal disorders]. Rehabilitation (Stuttg) 2006; 45:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/4\">",
"      Dufour AB, Broe KE, Nguyen US, et al. Foot pain: is current or past shoewear a factor? Arthritis Rheum 2009; 61:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/5\">",
"      Farrow SJ, Kingsley GH, Scott DL. Interventions for foot disease in rheumatoid arthritis: a systematic review. Arthritis Rheum 2005; 53:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/6\">",
"      Williams AE, Rome K, Nester CJ. A clinical trial of specialist footwear for patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/7\">",
"      Clark H, Rome K, Plant M, et al. A critical review of foot orthoses in the rheumatoid arthritic foot. Rheumatology (Oxford) 2006; 45:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/8\">",
"      Hawke F, Burns J, Radford JA, du Toit V. Custom-made foot orthoses for the treatment of foot pain. Cochrane Database Syst Rev 2008; :CD006801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/9\">",
"      Grotle M, Hagen KB, Natvig B, et al. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord 2008; 9:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/10\">",
"      Messier SP, Loeser RF, Miller GD, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum 2004; 50:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/11\">",
"      Minor M. Physical activity and management of arthritis. Ann Behav Med 1991; 13:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/12\">",
"      Backman CL, Village J, Lacaille D. The Ergonomic Assessment Tool for Arthritis: development and pilot testing. Arthritis Rheum 2008; 59:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/13\">",
"      Miyazaki T, Wada M, Kawahara H, et al. Dynamic load at baseline can predict radiographic disease progression in medial compartment knee osteoarthritis. Ann Rheum Dis 2002; 61:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/14\">",
"      Pollo FE, Otis JC, Backus SI, et al. Reduction of medial compartment loads with valgus bracing of the osteoarthritic knee. Am J Sports Med 2002; 30:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/15\">",
"      Kemp G, Crossley KM, Wrigley TV, et al. Reducing joint loading in medial knee osteoarthritis: shoes and canes. Arthritis Rheum 2008; 59:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/16\">",
"      Hinman RS, Bennell KL. Advances in insoles and shoes for knee osteoarthritis. Curr Opin Rheumatol 2009; 21:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/17\">",
"      Shakoor N, Lidtke RH, Sengupta M, et al. Effects of specialized footwear on joint loads in osteoarthritis of the knee. Arthritis Rheum 2008; 59:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/18\">",
"      Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev 2009; :CD002759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/19\">",
"      Luukinen H, Lehtola S, Jokelainen J, et al. Pragmatic exercise-oriented prevention of falls among the elderly: a population-based, randomized, controlled trial. Prev Med 2007; 44:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/20\">",
"      McClure R, Turner C, Peel N, et al. Population-based interventions for the prevention of fall-related injuries in older people. Cochrane Database Syst Rev 2005; :CD004441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/21\">",
"      Howe TE, Rochester L, Jackson A, et al. Exercise for improving balance in older people. Cochrane Database Syst Rev 2007; :CD004963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/22\">",
"      Yip YB, Sit JW, Fung KK, et al. Effects of a self-management arthritis programme with an added exercise component for osteoarthritic knee: randomized controlled trial. J Adv Nurs 2007; 59:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/23\">",
"      Doi T, Akai M, Fujino K, et al. Effect of home exercise of quadriceps on knee osteoarthritis compared with nonsteroidal antiinflammatory drugs: a randomized controlled trial. Am J Phys Med Rehabil 2008; 87:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/24\">",
"      Westby MD. A health professional's guide to exercise prescription for people with arthritis: a review of aerobic fitness activities. Arthritis Rheum 2001; 45:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/25\">",
"      Hinman RS, Heywood SE, Day AR. Aquatic physical therapy for hip and knee osteoarthritis: results of a single-blind randomized controlled trial. Phys Ther 2007; 87:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/26\">",
"      Jenkinson CM, Doherty M, Avery AJ, et al. Effects of dietary intervention and quadriceps strengthening exercises on pain and function in overweight people with knee pain: randomised controlled trial. BMJ 2009; 339:b3170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/27\">",
"      de Jong Z, Vliet Vlieland TP. Safety of exercise in patients with rheumatoid arthritis. Curr Opin Rheumatol 2005; 17:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/28\">",
"      de Jong Z, Munneke M, Zwinderman AH, et al. Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 2003; 48:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32407/abstract/29\">",
"      van den Ende CH, Breedveld FC, le Cessie S, et al. Effect of intensive exercise on patients with active rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2000; 59:615.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7763 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32407=[""].join("\n");
var outline_f31_41_32407=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18569439\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF JOINT PROTECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Respect pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reduce excess body weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Posture and body mechanics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Minimum force",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8247850\">",
"      Regular exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RESOURCES FOR TASK-RELATED PAIN (OCCUPATIONAL INJURIES)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18569439\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7763\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7763|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/40/18050\" title=\"picture 1\">",
"      Incorrect lifting knees straight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/51/816\" title=\"picture 2\">",
"      Proper lifting knees bent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/33/27152\" title=\"picture 3\">",
"      Reduce lower limb fatigue standing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/24/34191\" title=\"picture 4\">",
"      Improper twisting carrying load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/24/32143\" title=\"picture 5\">",
"      Proper movement avoid twisting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/5/34911\" title=\"picture 6\">",
"      Proper mechanics centering load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/13/37087\" title=\"picture 7\">",
"      Proper sitting posture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/49/26399\" title=\"picture 8\">",
"      Proper knee position squat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/32/37391\" title=\"picture 9\">",
"      Stationary biking",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30085?source=related_link\">",
"      Joint protection program for the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/40/37508?source=related_link\">",
"      Joint protection program for the upper limb",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35896?source=related_link\">",
"      Overview of joint protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29370?source=related_link\">",
"      Risk factors for and possible causes of osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_41_32408="Mirtazapine: Drug information";
var content_f31_41_32408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mirtazapine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/45/33493?source=see_link\">",
"    see \"Mirtazapine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F197109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Remeron SolTab&reg;;",
"     </li>",
"     <li>",
"      Remeron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Mirtazapine&reg;;",
"     </li>",
"     <li>",
"      Auro-Mirtazapine;",
"     </li>",
"     <li>",
"      Ava-Mirtazapine;",
"     </li>",
"     <li>",
"      CO Mirtazapine;",
"     </li>",
"     <li>",
"      Dom-Mirtazapine;",
"     </li>",
"     <li>",
"      GD-Mirtazapine;",
"     </li>",
"     <li>",
"      Jamp-Mirtazapine;",
"     </li>",
"     <li>",
"      Mylan-Mirtazapine;",
"     </li>",
"     <li>",
"      Novo-Mirtazapine;",
"     </li>",
"     <li>",
"      PMS-Mirtazapine;",
"     </li>",
"     <li>",
"      PRO-Mirtazapine;",
"     </li>",
"     <li>",
"      ratio-Mirtazapine;",
"     </li>",
"     <li>",
"      Remeron&reg;;",
"     </li>",
"     <li>",
"      Remeron&reg; RD;",
"     </li>",
"     <li>",
"      Riva-Mirtazapine;",
"     </li>",
"     <li>",
"      Sandoz-Mirtazapine;",
"     </li>",
"     <li>",
"      Sandoz-Mirtazapine FC;",
"     </li>",
"     <li>",
"      ZYM-Mirtazapine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F197140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Alpha-2 Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F197114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Initial: 15 mg nightly, may titrate dose up no more frequently than every 1-2 weeks to a maximum of 45 mg daily; dosage range: 15-45 mg daily; there is an inverse relationship between dose and sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Post-traumatic stress disorder (PTSD) (unlabeled use):",
"     </b>",
"     Oral: 30-60 mg daily (Bandelow, 2008; Benedek, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of mirtazapine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing mirtazapine and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate mirtazapine in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving mirtazapine and potential benefits outweigh potential risks, discontinue mirtazapine promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume mirtazapine 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F197115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing. Use with caution. Compared to younger adults, clearance is decreased 40% in elderly males and 10% in elderly females; manufacturer&rsquo;s labeling does not include specific dosage adjustment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alzheimer&rsquo;s dementia-related depression (unlabeled use): Initial: 7.5 mg at bedtime; may increase at 7.5-15 mg increments to 45-60 mg daily (Rabins, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F197116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; clearance is decreased 30% in moderate (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     11-39 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) impairment and is decreased 50% in severe (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) impairment. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F197117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is provided in manufacturer&rsquo;s labeling; a decrease in clearance by 30% has been observed in hepatic impairment. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F197086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 7.5 mg, 15 mg, 30 mg, 45 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remeron&reg;: 15 mg, 30 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remeron&reg;: 45 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 15 mg, 30 mg, 45 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remeron SolTab&reg;: 15 mg [contains phenylalanine 2.6 mg/tablet; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remeron SolTab&reg;: 30 mg [contains phenylalanine 5.2 mg/tablet; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remeron SolTab&reg;: 45 mg [contains phenylalanine 7.8 mg/tablet; orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F197070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Remeron&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089021.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089021.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Remeron SolTab&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM289881.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM289881.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F197089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orally disintegrating tablet: Administer without regard to meals.  Open blister pack and place tablet on the tongue; tablet is formulated to dissolve on the tongue without water; do not split tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Administer without regard to meals. Canadian labeling does not recommend chewing tablet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F197087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8109444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alzheimer&rsquo;s dementia-related depression; post-traumatic stress disorder (PTSD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F197147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Remeron&reg; may be confused with Premarin&reg;, ramelteon, Rozerem&reg;, Zemuron&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (SIADH: Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Avanza [Australia] may be confused with Albenza brand name for albendazole [U.S.]; Avandia brand name for rosiglitazone [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Remeron [U.S., Canada, and multiple international markets] may be confused with Reneuron which is a brand name for fluoxetine [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F197138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (54%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (25%), appetite increased (17%), constipation (13%), weight gain (12%; weight gain of &gt;7% reported in 8% of adults, &le;49% of pediatric patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (2%), edema (1%), hypertension, vasodilatation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (7%), abnormal dreams (4%), abnormal thoughts (3%), confusion (2%), agitation, amnesia, anxiety, apathy, depression, hyper/hypokinesia, hypoesthesia, malaise, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency (2%), urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: SGPT increased (&ge;3 times ULN: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (8%), back pain (2%), myalgia (2%), tremor (2%), arthralgia, myasthenia, paresthesia, twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (1%), cough increased, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (5%), thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdomen enlarged, abnormal ejaculation, accommodation abnormality, acid phosphatase increased, acne, akathisia, alopecia, ALT increased, amenorrhea, anemia, angina pectoris, aphasia, aphthous stomatitis, arthrosis, arthritis, asphyxia, AST increased, asthma, ataxia, atrial arrhythmia, bigeminy, blepharitis, bone pain, bradycardia, breast engorgement, breast enlargement, breast pain, bronchitis, bursitis, cardiomegaly, cellulitis, cerebral ischemia, chest pain, chills, cholecystitis, cirrhosis, colitis, conjunctivitis, coordination abnormal, cystitis, deafness, dehydration, delirium, delusions, dementia, depersonalization, diabetes mellitus, diplopia, drug dependence, dry skin, dysarthria, dyskinesia, dysmenorrhea, dystonia, dysuria, ear pain, emotional lability, epistaxis, eructation, euphoria, exfoliative dermatitis, extrapyramidal syndrome, eye pain, facial edema, fever, fracture, gastritis, gastroenteritis, glaucoma, glossitis, goiter, gout, grand mal seizure, gum hemorrhage, hallucinations, healing abnormalities, hematuria, herpes simplex, herpes zoster, hiccup, hostility, hyperacusis, hyponatremia, hypotension, hypothyroidism, hypotonia, impotence, intestinal obstruction, keratoconjunctivitis, kidney calculus, lacrimation disorder, laryngitis, left heart failure, leukopenia, leukorrhea, libido increased, liver function tests abnormal, lymphadenopathy, lymphocytosis, manic reaction, menorrhagia, metrorrhagia, migraine, MI, myoclonus, myositis, nausea, neck pain, neck rigidity, neurosis, nystagmus, oral moniliasis, osteoporosis, otitis media, pancreatitis, pancytopenia, paralysis, paranoid reaction, parosmia, petechia, phlebitis, photosensitivity reaction, pneumonia, pneumothorax, polyuria, psychotic depression, pulmonary embolus, reflexes increased, salivary gland enlargement, salivation increased, seborrhea, serotonin syndrome, skin hypertrophy, skin reactions (severe [including Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme, toxic epidermal necrolysis]), skin ulcer, stomatitis, stupor, syncope, taste loss, tendon rupture, tenosynovitis, thrombocytopenia, tongue discoloration, tongue edema, torsade de pointes (rare), ulcer, ulcerative stomatitis, urethritis, urinary incontinence, urinary retention, urinary urgency, urticaria, vaginitis, vascular headache, ventricular extrasystoles, weight loss, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F197092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mirtazapine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either mirtazapine or the MAO inhibitor); initiation of mirtazapine in a patient receiving linezolid or intravenous methylene blue",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F197074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Mirtazapine is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Akathisia/psychomotor restlessness: Most likely to occur within first few weeks of treatment and characterized by unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. Increasing the dose in these patients may be detrimental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is low relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Discontinue immediately if signs and symptoms of neutropenia/agranulocytosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: May increase serum cholesterol and triglyceride levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyponatremia: Use caution in patients at risk, such as elderly or patients concomitantly treated with medications known to cause hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is low relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is moderate to high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: The incidence of sexual dysfunction with mirtazapine is generally lower than with SSRIs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: May increase appetite and stimulate weight gain. In clinical trials, an increased incidence of weight gain in adults and children was observed with mirtazapine compared to placebo; up to 8% of patients discontinued therapy due to weight gain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Clinically significant transaminase elevations have been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Mirtazapine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use  caution in  elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Tablets contain lactose. Canadian labeling recommends avoiding use in patients with galactose intolerance or glucose-galactose malabsorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: SolTab&reg; formulation contains phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: May cause dizziness, abnormal dreams, sensory disturbances (including paresthesia and electric shock sensations), agitation, anxiety, fatigue, confusion, headache, tremor, nausea, vomiting, and sweating. Upon discontinuation of mirtazapine therapy, gradually taper dose.  If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, then resuming the previous dose with a more gradual taper should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F197134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F197079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Antidepressants (Alpha2-Antagonist) may diminish the antihypertensive effect of Alpha2-Agonists.  Management: Consider avoiding concurrent use.  If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if an alpha2-antagonist is initiated/dose increased, or increased effects if an alpha2-antagonist is discontinued/dose decreased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Mirtazapine. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the neurotoxic (central) effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Mirtazapine may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Mirtazapine. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Mirtazapine may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F197106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease mirtazapine levels). Avoid valerian, St John's wort, tryptophan, SAMe, kava kava (may increase CNS depression and/or increase the risk of serotonin syndrome).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F197081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F197096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. A significant increase in major teratogenic effects has not been observed in humans following exposure to mirtazapine during pregnancy; however, some nonteratogenic adverse events (similar to those observed with SSRI agents) have been reported (Djulus, 2006; Einarson, 2009; Lennest&aring;l, 2007). Mirtazapine was found to cross the placenta following a maternal overdose (Hatzidaki, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACOG recommends that therapy with antidepressants during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. Consideration should be given to using agents with safety data in pregnancy. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (ACOG, 2008; APA, 2010; Yonkers, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F197119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6825184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mirtazapine and its active metabolite are found in breast milk, with higher levels in the hindmilk than foremilk. Mirtazapine can also be detected in the serum of nursing infants; adverse events have generally not been observed, although possible sedation and weight gain was noted in one case report (Kristensen, 2007; Tonn, 2009). The manufacturer recommends that caution be used if administered to a breast-feeding woman.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F197097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F197095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Mirtazapine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (30): $77.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $80.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (30): $85.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Remeron SolTab Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (1): $4.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (1): $4.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (1): $4.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mirtazapine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (30): $79.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (30): $81.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $83.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (30): $85.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Remeron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (30): $151.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $155.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg (30): $158.68",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F197083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients should be monitored for signs of agranulocytosis or severe neutropenia such as sore throat, stomatitis or other signs of infection or a low WBC; renal and hepatic function; mental status for depression, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; signs/symptoms of serotonin syndrome; lipid profile; weight gain",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F197098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Afloyan (ES);",
"     </li>",
"     <li>",
"      Avanza (AU, NZ);",
"     </li>",
"     <li>",
"      Avanza Soltab (AU);",
"     </li>",
"     <li>",
"      Axit (AU);",
"     </li>",
"     <li>",
"      Ciblex (CN);",
"     </li>",
"     <li>",
"      Menelat (PH);",
"     </li>",
"     <li>",
"      Mi Er Ning (CL);",
"     </li>",
"     <li>",
"      Mirazep (IN, PH);",
"     </li>",
"     <li>",
"      Mirtapax (CO, EC);",
"     </li>",
"     <li>",
"      Mirtax (KP);",
"     </li>",
"     <li>",
"      Mirtazon (AU);",
"     </li>",
"     <li>",
"      Norset (FR);",
"     </li>",
"     <li>",
"      Noxibel (EC);",
"     </li>",
"     <li>",
"      Remergil (DE);",
"     </li>",
"     <li>",
"      Remergon (BE);",
"     </li>",
"     <li>",
"      Remeron (AE, AR, AT, AU, BH, BR, CH, CL, CO, CR, CY, CZ, DK, DO, EE, EG, FI, GR, GT, HN, ID, IL, IQ, IR, IT, JO, KP, KW, LB, LY, MX, MY, NI, NL, NO, OM, PA, PE, PK, PL, PT, QA, RU, SA, SE, SG, SV, SY, TR, TW, UY, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Remeron SolTab (CO, HK, PH, SG);",
"     </li>",
"     <li>",
"      Remirta (BG);",
"     </li>",
"     <li>",
"      Remixil ODT (KP);",
"     </li>",
"     <li>",
"      Sinmaron (TW);",
"     </li>",
"     <li>",
"      U-Mirtaron (TW);",
"     </li>",
"     <li>",
"      Vastat Flas (ES);",
"     </li>",
"     <li>",
"      Zispin (GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F197073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mirtazapine is a tetracyclic antidepressant that works by its central presynaptic alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic antagonist effects, which results in increased release of norepinephrine and serotonin. It is also a potent antagonist of 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     serotonin receptors and H1 histamine receptors and a moderate peripheral alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic and muscarinic antagonist; it does not inhibit the reuptake of norepinephrine or serotonin.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F197091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 4.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP1A2, 2C9, 2D6, 3A4 and via demethylation (forms demethylmirtazapine, an active metabolite) and hydroxylation (forms inactive metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 20-40 hours; increased with renal or hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (75%) and feces (15%) as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abo-Zena RA, Bobek MB, and Dweik RA, &ldquo;Hypertensive Urgency Induced by an Interaction of Mirtazapine and Clonidine,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2000, 20(4):476-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/10772378/pubmed\" id=\"10772378\" target=\"_blank\">",
"        10772378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins--Obstetrics, \"ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Psychiatric Association, \"Treatment Recommendations for Patients With Major Depressive Disorder,\" 3rd ed, May 2010. Available at file://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2008, 9(4): 248-312. Available at file://www.wfsbp.org/fileadmin/pdf/guides/Guidelines_Anxiety_revision.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/18949648/pubmed\" id=\"18949648\" target=\"_blank\">",
"        18949648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at  file://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=AcuteStressDisorder-PTSD_GuidelineWatch",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berigan TR, &ldquo;Mirtazapine-Associated Withdrawal Symptoms; A Case Report,&rdquo;",
"      <i>",
"       Primary Care Companion J Clin Psychiatry",
"      </i>",
"      ,  2001, 3(3):143.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/15014614/pubmed\" id=\"15014614\" target=\"_blank\">",
"        15014614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Djulus J, Koren G, Einarson TR, et al, \"Exposure to Mirtazapine During Pregnancy: A Prospective, Comparative Study of Birth Outcomes,\"",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2006, 67(8):1280-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einarson A, Choi J, Einarson TR, et al, \"Incidence of Major Malformations in Infants Following Antidepressant Exposure in Pregnancy: Results of a large Prospective Cohort Study,\"",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2009, 54(4):242-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/19321030/pubmed\" id=\"19321030\" target=\"_blank\">",
"        19321030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hatzidaki E, Toutoudaki M, Christaki, et al, \"A Non-Fatal Suicide Attempt of a Pregnant Woman Using Mirtazapine and Venlafaxine,\"",
"      <i>",
"       Toxicol Lett",
"      </i>",
"      , 2008, 180(Suppl):S141-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kristensen JH, Ilett KF, Rampono J, et al, \"Transfer of the Antidepressant Mirtazapine Into Breast Milk,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2007, 63(3):322-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/16970569/pubmed\" id=\"16970569\" target=\"_blank\">",
"        16970569",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lennest&aring;l R and K&auml;ll&eacute;n B, \"Delivery Outcome in Relation to Maternal Use of Some Recently Introduced Antidepressants,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2007, 27(6):607-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/18004128/pubmed\" id=\"18004128\" target=\"_blank\">",
"        18004128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stimmel GL, Dopheide JA, and Stahl SM, &ldquo;Mirtazapine: An Antidepressant With Noradrenergic and Specific Serotonergic Effects,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1997, 17(1):10-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/9017762/pubmed\" id=\"9017762\" target=\"_blank\">",
"        9017762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tonn P, Reuter SC, Hiemke C, et al, \"High Mirtazapine Plasma Levels in Infant After Breast Feeding: Case Report and Review of the Literature,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2009, 29(2):191-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/19512989/pubmed\" id=\"19512989\" target=\"_blank\">",
"        19512989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/41/32408/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9656 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32408=[""].join("\n");
var outline_f31_41_32408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709090\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197109\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197110\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197140\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197114\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197115\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197116\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197117\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197086\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197070\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874926\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197089\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197087\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8109444\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197147\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197138\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197092\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197074\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197134\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197079\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197106\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197081\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197096\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197119\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6825184\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197097\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197095\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197083\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197098\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197073\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197091\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9656\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9656|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/45/33493?source=related_link\">",
"      Mirtazapine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_41_32409="Echocardiographic evaluation of the mitral valve";
var content_f31_41_32409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic evaluation of the mitral valve",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/41/32409/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32409/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32409/contributors\">",
"     Xiushui Ren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/41/32409/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32409/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32409/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/41/32409/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32409/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/41/32409/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mitral valve was the first structure to be identified by echocardiography (",
"    <a class=\"graphic graphic_figure graphicRef79932 \" href=\"mobipreview.htm?5/22/5476\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Technical advances have enabled echocardiography to identify almost any anatomic or functional abnormality of the mitral valve. The appearance of the normal mitral valve and the more commonly encountered mitral valvular abnormalities will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL MITRAL VALVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard transthoracic echocardiographic examination (TTE) of the mitral valve consists of an M-mode tracing, multiple two-dimensional views, and Doppler flow evaluation. If clinically indicated (eg, technically difficult TTE or evaluation of prosthetic paravalvular leak), a transesophageal echocardiogram (TEE) may be performed. Together, these elements form an integrated examination of the mitral valve that can reliably define its function and evaluate the severity of abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anatomically, the orientation of the anterior leaflet of the mitral valve places this broad surface toward the anterior chest wall, making it an ideal sound reflecting target. Furthermore, because of its relatively large margin-to-base ratio, the anterior leaflet is highly mobile (",
"    <a class=\"graphic graphic_figure graphicRef57906 \" href=\"mobipreview.htm?6/27/6576\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mitral valve can be recorded by ultrasound through a variety of anatomic windows in the precordium, apical, and subxiphoid regions, all of which should be used in its examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     M-mode echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The M-mode examination is performed from the precordium and guided from the two-dimensional long and short axis views. Normally, the anterior mitral leaflet exhibits a motion pattern that reflects the phasic nature of ventricular filling and produces a familiar M-shaped pattern (",
"    <a class=\"graphic graphic_figure graphicRef67656 \" href=\"mobipreview.htm?37/54/38759\">",
"     figure 3",
"    </a>",
"    ). The posterior leaflet moves in a nearly mirror image \"W\" pattern with a smaller excursion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial large opening diastolic movement of the valve, which culminates in the E-point, is the result of rapid left ventricular filling.",
"     </li>",
"     <li>",
"      The valve assumes a nearly closed position during the middle of diastole (F point), reflecting the deceleration of inflow as the pressure gradient between atrium and ventricle is reduced. On the M-mode echocardiogram, this early diastolic closure is measured as the E-F slope, which is usually &gt;60",
"      <span class=\"nowrap\">",
"       mm/sec.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During this mid-diastolic phase, in spite of the appearance of closure, there continues to be flow of blood from pulmonary veins to the left ventricle. This period of filling is known as the conduit phase because the atrium briefly functions as a passive channel rather than a reservoir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following atrial contraction, the valve opens for a second time (A point), completing the second peak of the letter M.",
"     </li>",
"     <li>",
"      Final closure is probably the combined effect of deceleration of atrial inflow and isometric LV contraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Two-dimensional echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two-dimensional appearance of the normal mitral valve on TTE depends somewhat upon the imaging plane from which it is viewed. In the parasternal short axis plane, the valve presents itself as an ovoid (fish mouth) orifice (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68826 \" href=\"mobipreview.htm?10/30/10735\">",
"     image 1",
"    </a>",
"    ), while in parasternal long axis and apical views, it resembles clapping hands, with the anterior hand longer and more mobile than the posterior (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77446 graphicRef75034 \" href=\"mobipreview.htm?15/36/15941\">",
"     image 2A-B",
"    </a>",
"    ). In general, the normal mitral valve should appear as a mobile, two leaflet structure that moves freely enough to respond to the normal flux of diastolic filling but forms a stable coaptation plane in systole without breaking the plane defined by the mitral annulus and entering the body of the left atrium.",
"   </p>",
"   <p>",
"    Anatomically, the mitral valve leaflets are thin and translucent; the rough attachment points of its chordae to their free margins are thicker than their smooth bellies. The chordae from each leaflet connect to both papillary muscles. On M-mode, each leaflet is represented by no more than two linear echoes. On two-dimensional imaging, the valve appears homogeneous and thin, &lt;4 mm in thickness. However, the perception of leaflet thickness also depends upon the transducer frequency.",
"   </p>",
"   <p>",
"    Many sonographers prefer 2.5 mHz for imaging because it allows adequate images in difficult patients and is superior for Doppler flow. At this lower frequency, some normal valves can appear mildly thickened. For this reason, if an abnormality is suspected, the valve should be imaged with a higher frequency before being designated as \"thickened.\" In order to exclude valve pathology, fundamental (non-harmonic) imaging at 3.5 mHz or higher should be used. As a general rule, when imaged fundamentally, a normal mitral valve is thinner than a normal aortic root imaged under the same conditions.",
"   </p>",
"   <p>",
"    Other anatomic features of the mitral apparatus that are appreciated on two-dimensional echocardiographic examination include the papillary muscles, chordae, and the mitral annulus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The papillary muscles can be seen in the parasternal short axis at approximately four o'clock (anterolateral) and eight o'clock (posteromedial) orientations, and their fine anatomy is highly variable.",
"     </li>",
"     <li>",
"      The mitral annulus is receiving increasing attention because three-dimensional imaging has revealed it to be highly dynamic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/5\">",
"       5",
"      </a>",
"      ]. On two-dimensional imaging, the examination is limited to measuring the diameter of the mitral annulus and inspecting it for calcification (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60748 \" href=\"mobipreview.htm?39/11/40115\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61639 \" href=\"mobipreview.htm?21/38/22112\">",
"       image 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef56296 \" href=\"mobipreview.htm?9/57/10129\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Doppler echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler examination of the normal mitral valve reveals that the velocity pattern of blood entering the left ventricle during diastole closely resembles the M-shaped pattern of the M-mode of that structure; blood flow is most rapid during the early (E) phases of filling, falls to very low levels during the mid-diastolic conduit phase, and accelerates again during atrial (A) contraction. Transmitral flow is sampled from the apical four chamber view; the sampling site used to obtain this signal is the space between the tips of the open mitral valve (",
"    <a class=\"graphic graphic_waveform graphicRef59321 \" href=\"mobipreview.htm?5/31/5618\">",
"     waveform 2",
"    </a>",
"    ). When transmitral flow is used to quantitate flow volume, the sample volume is placed in the mitral annulus. The normal peak flow velocity across the mitral valve is usually just under 1",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    and the normal mitral valve area is 4 to 6 cm2.",
"   </p>",
"   <p>",
"    Many measurements are derived from the transmitral wave form. The most reliable and relevant measurements are the ratio of the E to A waves, the isovolemic relaxation time, and the deceleration time. These values give insight into diastolic function and into the function of the valve (",
"    <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"mobipreview.htm?31/45/32470\">",
"     waveform 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MITRAL VALVE LESIONS CAUSING INFLOW OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common lesion of the mitral valve that causes inflow obstruction is mitral stenosis, which is usually acquired as the result of rheumatic heart disease. Less common causes include left atrial myxoma and other tumors, severe mitral annular calcification, left-sided carcinoid heart disease, and congenital disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13610?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=see_link\">",
"     \"Carcinoid heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mitral stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In mitral stenosis, the normal, rapid, biphasic motion of the valve is altered because the valve opens only partly and as a single unit. Anatomically, the commissural separation between the anterior and posterior or mural leaflets is diminished by partial fusion and the subvalvular apparatus is altered by chordal foreshortening. Immobility of the posterior leaflet is a common early finding with a \"hockey",
"    <span class=\"nowrap\">",
"     stick/knee",
"    </span>",
"    bend\" appearance to the anterior mitral leaflet due to leaflet tethering. Doming of the anterior leaflet corresponds temporally to the opening snap on auscultation.",
"   </p>",
"   <p>",
"    These changes cause a limiting orifice that obstructs diastolic transit of blood from atrium to ventricle. One hemodynamic consequence of this alteration is a holodiastolic pressure gradient between the left atrium and left ventricle.",
"   </p>",
"   <p>",
"    TTE can identify the pathologic entity of mitral stenosis and quantitate its severity with sufficient accuracy to make reliable decisions about the suitability for catheter-based balloon valvotomy or the need for surgery. Quantitation of mitral stenosis severity can be accomplished by direct methods, and its qualitative estimation by a number of indirect observations.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines of valvular heart disease gave a Class I recommendation for the use of TTE in diagnosing the presence and evaluating the severity of mitral stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     M-mode echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;M-mode confirmation of the altered pattern of mitral motion in mitral stenosis remains a useful tool. Mitral stenosis alters the appearance of the M-mode tracing of the mitral valve so that its normal early diastolic closure is delayed or abolished. The early diastolic closure slope, the E-F slope, produces an easily recognized pattern and can also be quantitated to separate normal atrial inflow from obstructed and to differentiate among the degrees of obstruction (",
"    <a class=\"graphic graphic_figure graphicRef73666 graphicRef57949 graphicRef65631 \" href=\"mobipreview.htm?27/50/28456\">",
"     figure 4A-C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef50915 \" href=\"mobipreview.htm?30/8/30863\">",
"     movie 1",
"    </a>",
"    ). Although this method is the least reliable means of quantitating the severity of obstruction, a slope of less than 10",
"    <span class=\"nowrap\">",
"     mm/sec",
"    </span>",
"    (normal is &gt;60",
"    <span class=\"nowrap\">",
"     mm/sec)",
"    </span>",
"    from a valve recording made during suspended respiration is evidence for severe mitral stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/7\">",
"     7",
"    </a>",
"    ]. In normal valves, the posterior leaflet moves in a mirror image pattern to the anterior; in mitral stenosis, the posterior leaflet moves forward in diastole, paralleling the anterior. Reversal of diastolic motion from the normal pattern makes the M-mode of the posterior leaflet one of the most valuable means of identifying mitral stenosis.",
"   </p>",
"   <p>",
"    The opening snap (OS) of the mitral valve coincides with the initial peak opening (E) of the valve (",
"    <a class=\"graphic graphic_picture graphicRef73087 \" href=\"mobipreview.htm?31/52/32578\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Two-dimensional TTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral stenosis alters the appearance of the valve on two-dimensional echocardiography because it partially fuses the normally independent leaflets and creates a persistent gradient between the left ventricle and left atrium. This gradient keeps the stenotic diastolic orifice opened to its maximum and causes the entire valve to dome or bulge into the ventricle throughout diastole (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71983 \" href=\"mobipreview.htm?0/39/624\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef78565 \" href=\"mobipreview.htm?3/0/3074\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef62748 \" href=\"mobipreview.htm?18/60/19393\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef71501 \" href=\"mobipreview.htm?7/49/7957\">",
"     movie 4",
"    </a>",
"    ). The elevated gradient initiates the opening motion in an abrupt manner, generating the opening snap and a characteristic \"knee bend\" appearance on the precordial long axis view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73951 \" href=\"mobipreview.htm?21/1/21520\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef76132 \" href=\"mobipreview.htm?19/32/19972\">",
"     movie 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the parasternal short axis plane, the opening of the valve can be imaged just above the tips of the papillary muscles. From this orientation, its maximum diastolic opening area can be measured by direct planimetry of the two-dimensional image. This method is a reliable means of judging the severity of obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A mitral valve area (MVA) of less than 1.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    is considered severe, regardless of the method used to calculate its size.",
"   </p>",
"   <p>",
"    Other features of mitral stenosis on the two-dimensional echocardiogram include chordal foreshortening and atrial thrombi; the latter are rarely seen in echocardiograms taken from the precordial windows.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler methods provide a constellation of measurements by which the severity of mitral stenosis is gauged. These variables include the gradient across the valve at rest and with exercise, the inferred area by the pressure half-time method, the continuity equation or the proximal flow convergence method, and the pulmonary pressure at rest and during exercise from the tricuspid regurgitant jet velocity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doppler methods can measure the velocity of mitral inflow. In mitral stenosis, this velocity increases at rest from a normal value of less than 1",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    to greater than 1.5",
"    <span class=\"nowrap\">",
"     m/sec.",
"    </span>",
"    The algorithm to convert Doppler velocity into pressure gradient is the modified Bernoulli equation. The peak gradient between two reservoirs connected by a narrow orifice or pipe (in this case the left ventricle and the left atrium connected by the stenotic mitral valve) can be calculated by the modified Bernoulli formula, taking the square of the peak velocity of fluid flowing between them (in this case, blood) and multiplying by four (",
"    <a class=\"graphic graphic_movie graphicRef68524 \" href=\"mobipreview.htm?10/44/10959\">",
"     movie 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef52554 \" href=\"mobipreview.htm?29/43/30399\">",
"     movie 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef52855 \" href=\"mobipreview.htm?4/59/5048\">",
"     waveform 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;Peak gradient, in mmHg &nbsp;= &nbsp;4 &nbsp;x &nbsp;peak velocity(2)",
"   </p>",
"   <p>",
"    Thus, a peak velocity of 1",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    indicates a peak gradient of 4 mmHg; a peak velocity of 2",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    indicates a peak gradient of 16 mmHg; 3",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    indicates a peak gradient of 36 mmHg.",
"   </p>",
"   <p>",
"    The mean transmitral gradient can be measured by tracing the area-under-the-curve of the mitral E and A waves obtained by continuous wave Doppler. Severe mitral stenosis is defined by a mean transmitral gradient greater than 10 mmHg.",
"   </p>",
"   <p>",
"    The most frequently used measurement for the determination of the transmitral gradient during diastole is the pressure half-time, which is derived from hemodynamic data (",
"    <a class=\"graphic graphic_figure graphicRef65636 graphicRef64364 \" href=\"mobipreview.htm?31/57/32661\">",
"     figure 5A-B",
"    </a>",
"    ). The pressure half-time is the time required for the gradient between the left atrium and the left ventricle to fall to one-half of its initial value. In order to convert Doppler velocity into a pressure gradient, the initial flow velocity is divided by 1.41 (square root of 2), because velocity bears a second order relationship to pressure. Empirically, a pressure half-time of 220 msec is equivalent to an MVA of 1.0 cm2; therefore:",
"   </p>",
"   <p>",
"    &nbsp;MVA &nbsp;= &nbsp;220 &nbsp;&divide; &nbsp;pressure half-time",
"   </p>",
"   <p>",
"    Calculating the MVA using the pressure half-time may be an inaccurate approach whenever abrupt changes in the transmitral gradient occur for reasons other than inflow obstruction. An example of such a change is additional ventricular filling from aortic regurgitation.",
"   </p>",
"   <p>",
"    Among the methods for estimating mitral stenosis severity, direct planimetry of the orifice is probably the most accurate when performed correctly. However, in a clinical setting, it is the universal practice to achieve cross validation by applying the full array of methods.",
"   </p>",
"   <p>",
"    Indirect methods to identify the severity of mitral stenosis include observing the degree of foreshortening of the chordae tendineae, estimating the extent of leaflet calcification, noting the degree of left atrial enlargement, noting the degree of left ventricular underloading (ie, volume decrease), noting the presence of right ventricular and atrial dilatation, and noting the degree of tricuspid regurgitation and pulmonary hypertension, as determined by Doppler of tricuspid regurgitant jet.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on valvular heart disease defined severe mitral stenosis as having a mean transmitral gradient greater than 10 mmHg, pulmonary artery systolic pressure greater than 50 mmHg, and an MVA of less than 1.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Documentation of a transmitral gradient pulmonary pressure elevation during exercise is useful in patients whose symptoms do not seem concordant with the degree of mitral stenosis at rest. In patients who cannot exercise,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    has been used to increase heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/12\">",
"     12",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    recommended exercise echocardiography in evaluating the severity of mitral stenosis when there is a discrepancy between the resting echocardiographic findings and clinical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35319?source=see_link&amp;anchor=H17#H17\">",
"     \"Protocols for stress echocardiography\", section on 'Mitral stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Three-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional echocardiography (3-D echo) has been evaluated for its utility in assessing mitral stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This technique can provide an en-face cross sectional view of the mitral orifice, to which planimetry can be applied to determine the MVA. Compared with two-dimensional echocardiography, it performs better when cardiac catheterization derived MVA is used as the gold standard. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23146?source=see_link&amp;anchor=H10#H10\">",
"     \"Three-dimensional echocardiography\", section on 'Valvular heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Echocardiography in balloon valvuloplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of echocardiography in mitral stenosis has become even more demanding with the development of catheter-based palliative interventions. These interventions require a transseptal puncture to deliver a dilating balloon across the obstructed mitral orifice. When successful, these techniques offer dramatic relief of symptoms and may avoid surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The likelihood of success of balloon valvotomy can be judged with TTE by grading the severity of involvement of elements of the mitral valve on scale of 1 through 4, with a score of 1 representing normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The four elements are the mobility of the anterior leaflet, the severity of subvalvular disease, the calcification of the anterior leaflet, and the thickness of the anterior leaflet. The value for each of these four scores is added together for a total \"splitability index\" of 4 to 16, with a score of 8 or less indicating a higher probability of success.",
"   </p>",
"   <p>",
"    Other studies have proposed an alternate means of judging suitability for valvotomy by the location and distribution of calcium around the stenotic orifice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/17\">",
"     17",
"    </a>",
"    ]. Mitral regurgitation is not included in any of these indices, but a degree of mitral regurgitation more than mild is considered a relative contraindication to the procedure. Indeed, severe mitral regurgitation, occurring as a complication of the procedure, often requires urgent valve replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mitral annular calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral annular calcification (MAC) is a common echocardiographic finding associated with aging, renal failure and other conditions. It is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37801?source=see_link\">",
"     \"Mitral annular calcification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital conditions that cause mitral stenosis are rarely encountered in adults. Parachute mitral valve (single papillary muscle), supravalvular mitral ring, and cor triatriatum are congenital conditions that obstruct mitral inflow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cor triatriatum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cor triatriatum is among the rarest of all congenital cardiac anomalies and is often a hemodynamically mild incidental finding. The membrane of cor triatriatum appears as a linear echo bisecting the left atrium, from right to left, into an upper chamber (embryonic common pulmonary vein) containing the pulmonary veins and a lower chamber (embryonic left atrium) leading to the mitral inflow tract. Color flow mapping usually demonstrates mild increases in velocity, suggesting minimal obstruction. This lesion may be resected in childhood as it may eventually lead to atrial dilation and symptomatic arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Left atrial myxoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left atrial myxoma, when mobile, may cause inflow obstruction by interposing its bulk in the mitral orifice (",
"    <a class=\"graphic graphic_movie graphicRef53539 \" href=\"mobipreview.htm?29/30/30178\">",
"     movie 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef80469 \" href=\"mobipreview.htm?3/55/3952\">",
"     movie 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef58730 \" href=\"mobipreview.htm?39/46/40673\">",
"     movie 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef71550 \" href=\"mobipreview.htm?28/31/29171\">",
"     movie 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef73495 \" href=\"mobipreview.htm?17/10/17571\">",
"     movie 12",
"    </a>",
"    ). When these rare tumors are encountered on two dimensional imaging, Doppler examination detects the degree of mechanical inflow obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other cardiac tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary malignant tumors of the heart, such as angiosarcomas and lymphomas, may mechanically deform and obstruct the mitral valve. Advanced lymphoma may engulf much of the mitral apparatus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Carcinoid heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid heart disease is a rare disease that, in most patients, involves only valves on the right side of the heart. However, left-sided involvement (mitral stenosis) can occur when there are bronchial metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=see_link\">",
"     \"Carcinoid heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ABNORMALITIES ASSOCIATED WITH MITRAL REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whereas stenotic lesions alter the diastolic motion pattern of the mitral valve and are readily identifiable by M-mode and two dimensional imaging, lesions associated with mitral regurgitation are often associated with subtle abnormalities of the valve elements. However, when the valve is obviously disrupted or partially flail, mitral regurgitation is likely to be severe (",
"    <a class=\"graphic graphic_movie graphicRef65945 \" href=\"mobipreview.htm?30/49/31504\">",
"     movie 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef65137 \" href=\"mobipreview.htm?31/23/32115\">",
"     movie 14",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef57557 \" href=\"mobipreview.htm?23/5/23646\">",
"     movie 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef80563 \" href=\"mobipreview.htm?10/37/10835\">",
"     waveform 5",
"    </a>",
"    ). In contrast to anatomic imaging methods, Doppler flow imaging is highly sensitive in detecting mitral regurgitation of all severities, and is the most important part of the ultrasound examination for mitral regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Determination of severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over twenty variables for judging the severity of mitral regurgitation have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/3\">",
"     3",
"    </a>",
"    ]. Employing this approach, severe lesions are readily recognized, but distinguishing among the intermediate grades of mitral regurgitation (mild to moderate, moderate to severe mitral regurgitation) is more difficult. To sort out this clinical problem, it is frequently useful to perform supine bicycle exercise to evaluate for an exaggerated rise in pulmonary pressure that typifies the more advanced degrees of mitral regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2003 American Society of Echocardiography's consensus statement on echocardiographic quantification of valvular regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/20\">",
"     20",
"    </a>",
"    ], corroborated by the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    consensus statement on management of valvular heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/6\">",
"     6",
"    </a>",
"    ], recommended using multiple parameters when determining the severity of mitral regurgitations. These parameters include structural, qualitative Doppler, and quantitative Doppler parameters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Structural parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural abnormalities associated with mitral regurgitation supplement the quantitation of regurgitation and include left atrial size, left ventricular size, and appearance of the mitral apparatus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild mitral regurgitation is usually associated with normal or near-normal left atrial size, left ventricular size, and intact mitral apparatus.",
"     </li>",
"     <li>",
"      Moderate mitral regurgitation is frequently associated with some degree of left atrial enlargement, normal or mildly dilated left ventricle, and varying degrees of mitral apparatus abnormalities.",
"     </li>",
"     <li>",
"      Severe chronic mitral regurgitation is usually associated with moderate to severe left atrial enlargement, some degree of left ventricular dilatation, and often associated with flail mitral leaflet, ruptured papillary muscle, or malcoaptation of the mitral leaflets.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Color flow Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;The features of severe mitral regurgitation seen by color flow Doppler imaging arise from the high energy transfer of a volume of blood into the left atrium, producing the characteristic \"jet\" in the left atrium (",
"    <a class=\"graphic graphic_movie graphicRef75955 \" href=\"mobipreview.htm?16/31/16884\">",
"     movie 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef63107 \" href=\"mobipreview.htm?8/37/8784\">",
"     movie 17",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef78402 \" href=\"mobipreview.htm?20/12/20672\">",
"     movie 18",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61846 \" href=\"mobipreview.htm?17/43/18099\">",
"     movie 19",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76485 \" href=\"mobipreview.htm?18/3/18483\">",
"     image 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/21\">",
"     21",
"    </a>",
"    ]. Color flow Doppler is usually considered a qualitative or semi-quantitative parameter.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In current practice, it is common to judge a small jet occupying less than 20 percent of the left atrial area as mild, a middle sized jet as moderate, and a large jet (more than 40 percent and extending into the pulmonary veins) as severe mitral regurgitation. However, these jets are very sensitive to instrument settings, and the size of a color jet may be misleading; thus, reliance on these size judgments alone is imprudent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the ventricular side of the valve, proximal flow acceleration (proximal isovelocity surface area or PISA) is seen as a concentric series of hemispheric rings of alternating colors, each ring denoting an isovelocity of aliasing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/22\">",
"       22",
"      </a>",
"      ]. The diameter of the ring closest to the regurgitant orifice is measured and, in severe mitral regurgitation, usually approaches 1 cm.",
"     </li>",
"     <li>",
"      After the color jet crosses the valve defect, the width of the jet increases. In the parasternal long-axis view, the narrowest portion of the regurgitant jet across the valve is defined as the vena contracta. Mild mitral regurgitation is usually associated with a vena contracta less than 0.3 cm, while severe mitral regurgitation is usually associated with a vena contracta of 0.7 cm or more [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As the jet of severe mitral regurgitation enters the left atrium, it becomes eccentric and hugs the wall of the chamber (entrainment or Coanda effect). Once entrained on the wall, the jet may completely circle the chamber. The jet also tends to penetrate the atrial appendage and one or more of the pulmonary veins. The color flow pattern in the receiving chamber is agitated and multidirectional, and spontaneous contrast is absent. During most of the jet's passage around the atrium, it is broad and aliased. It must be emphasized that any aliased (mosaic) wall hugging jet, however small in apparent area, should be considered to potentially represent severe mitral regurgitation. Generally, milder degrees of mitral regurgitation are associated with central jets that lose their mosaic pattern before reaching the atrial wall.",
"     </li>",
"     <li>",
"      Some researchers have found the jet area in the left atrium on TEE to be a useful guide to mitral regurgitation severity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/21\">",
"       21",
"      </a>",
"      ]. However, since the entire left atrium cannot be seen at one time, the measurement of total jet size is problematic. Furthermore, careful study of most jets with appropriate frame rates reveals that they are not central jets but entrained wall jets, which do not lend themselves to \"jet area measurement.\" We do not endorse this method.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Pulsed and continuous wave Doppler of mitral inflow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spectral Doppler (pulsed and continuous wave) recognition of severe mitral regurgitation also has many diagnostic features. In severe mitral regurgitation, the early diastolic mitral inflow pulsed-wave Doppler signal wave (E wave), obtained at the tips of the mitral leaflets, is almost always increased to greater than 1.4",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef66504 graphicRef76117 \" href=\"mobipreview.htm?27/12/27845\">",
"     figure 6A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to increased peak transmitral inflow E wave velocity, the pattern is strongly E-wave dominant with a small A-wave",
"    <span class=\"nowrap\">",
"     (E/A",
"    </span>",
"    ratio greater than 2.0). This pattern is identical to the restrictive inflow pattern and has a similar origin, in that filling pressures may be elevated in both situations. Finding an A-wave dominant pattern of mitral inflow makes severe mitral regurgitation very unlikely.",
"   </p>",
"   <p>",
"    Several features of the continuous wave Doppler systolic patterns of regurgitant mitral flow support the presence of severe mitral regurgitation. If the flow signal can be aligned parallel to the beam, the jet will appear uniformly dense throughout its duration, have a well-defined envelope, and may, in its late phases, show evidence of a \"v-wave cut-off sign.\" This sign results from a rapid decrease in ventriculoatrial gradient as the large volume of regurgitant blood abruptly raises pressure in the left atrium (",
"    <a class=\"graphic graphic_waveform graphicRef51062 \" href=\"mobipreview.htm?12/38/12899\">",
"     waveform 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In severe decompensated mitral regurgitation, the tricuspid regurgitation peak velocity is often increased as the result of pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Quantitative parameters of mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the proximal isovelocity surface area (PISA) method and various volumetric methods, quantitative measures including regurgitant volume, regurgitant fraction, and effective regurgitation orifice area (EROA) can be calculated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/20\">",
"     20",
"    </a>",
"    ]. Performed correctly, these parameters are considered most accurate because they are objective. However, measurements must be performed carefully by experienced sonographers. For example, the PISA signal must not impinge on a chamber wall in order to retain accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild mitral regurgitation is associated with regurgitant volume, regurgitant fraction, and EROA of less than 30",
"      <span class=\"nowrap\">",
"       ml/beat,",
"      </span>",
"      less than 30 percent, and less than 0.2 cm, respectively.",
"     </li>",
"     <li>",
"      Moderate mitral regurgitation is associated with regurgitant volume, regurgitant fraction, and EROA of 30 to 59",
"      <span class=\"nowrap\">",
"       ml/beat,",
"      </span>",
"      30 to 49 percent, and 0.2 to 0.39 cm, respectively.",
"     </li>",
"     <li>",
"      Severe mitral regurgitation is associated with regurgitant volume, regurgitant fraction, and EROA of at least 60",
"      <span class=\"nowrap\">",
"       mL/beat,",
"      </span>",
"      at least 50 percent, and at least 0.4 cm, respectively. However, if the left ventricular chamber size is normal, a diagnosis of severe mitral regurgitation should be questioned and reconsidered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Doppler of pulmonary veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler interrogation of the pulmonary veins has produced insights into hemodynamics. In mitral regurgitation, this evaluation is a standard part of the examination and usually includes pulse Doppler of the left and right upper pulmonary veins from the apical four-chamber view. Normal pulmonary venous flow is antegrade during both ventricular systole and diastole (ventricular systolic component dominates), with slight retrograde flow during atrial systole. In hemodynamically severe mitral regurgitation, the flow in one or more pulmonary veins (depending upon the direction of the jet) will show systolic flow reversal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62749 \" href=\"mobipreview.htm?17/35/17970\">",
"     image 8",
"    </a>",
"    ) and is the analog of the V wave seen in the left atrial pressure tracing and on a pulmonary artery wedge pressure tracing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Index of severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiographic index of mitral regurgitation severity has been developed and is based on six variables, each scored on a scale of 0 to 3 and then averaged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Color Doppler regurgitant jet width and penetration",
"     </li>",
"     <li>",
"      Color Doppler proximal isovelocity surface area diameter",
"     </li>",
"     <li>",
"      Continuous wave Doppler characteristics of the regurgitant jet",
"     </li>",
"     <li>",
"      Tricuspid regurgitant jet-derived pulmonary artery pressure by continuous wave Doppler",
"     </li>",
"     <li>",
"      Pulse wave Doppler pulmonary venous flow pattern",
"     </li>",
"     <li>",
"      Left atrial size by two-dimensional echocardiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the report presenting this index, all patients with mild mitral regurgitation had an index &le;1.7 and all patients with severe mitral regurgitation (regurgitant fraction greater than 40 percent) had a value of at least 1.8. A value of at least 2.2 identified patients with severe mitral regurgitation with a sensitivity, specificity, and positive predictive value of 90, 88, and 79 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MITRAL VALVE LESIONS CAUSING MITRAL REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes of mitral regurgitation are mitral valve prolapse, flail mitral valve, endocarditis, functional mitral regurgitation from cardiomyopathy, ischemic heart disease with papillary muscle displacement (previously known as papillary muscle dysfunction), and rheumatic heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9705?source=see_link\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/45/28376?source=see_link\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Mitral valve prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiographic diagnosis of mitral valve prolapse is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13705?source=see_link\">",
"     \"Definition and diagnosis of mitral valve prolapse\"",
"    </a>",
"    .) Briefly, leaflet displacement &ge;2 mm above the plane of the mitral annulus in long axis two-dimensional echocardiographic views is the accepted criterion for a positive diagnosis of mitral valve prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/6\">",
"     6",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Flail mitral valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of flail mitral valve leaflet, the leaflet is only partially flail. One of the most common causes for a flail mitral valve is ruptured chordae tendineae, often associated with mitral valve prolapse, endocarditis, or trauma (",
"    <a class=\"graphic graphic_movie graphicRef60709 \" href=\"mobipreview.htm?12/21/12628\">",
"     movie 20",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61846 \" href=\"mobipreview.htm?17/43/18099\">",
"     movie 19",
"    </a>",
"    ). A less common cause is partial rupture of a papillary muscle in the setting of an acute myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/6/11369?source=see_link\">",
"     \"Role of echocardiography in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two-dimensional TTE and TEE are the best methods for detecting a flail leaflet. Using the TTE parasternal long axis and apical four chamber views, extension of a portion of the valve into the left atrium in systole, with a portion of the chordae attached at the tip of the valve is readily seen (",
"    <a class=\"graphic graphic_movie graphicRef60709 \" href=\"mobipreview.htm?12/21/12628\">",
"     movie 20",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61846 \" href=\"mobipreview.htm?17/43/18099\">",
"     movie 19",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other findings of flail mitral leaflet include noncoaptation of the two leaflets. If the etiology is papillary muscle rupture, the ruptured papillary muscle can occasionally be visualized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Endocarditis of the mitral valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;For establishing a diagnosis of endocarditis, the first target of the echocardiography examination is the identification, characterization, and localization of valvular vegetations. The process integrates circumstantial findings and epiphenomena (eg, endocarditis is a destructive process resulting in pathologic regurgitation) to reach a reasonable conclusion that a given set of echocardiographic observations has identified the pathologic hallmark of endocarditis, the vegetation (",
"    <a class=\"graphic graphic_movie graphicRef53844 \" href=\"mobipreview.htm?1/25/1427\">",
"     movie 21",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66283 \" href=\"mobipreview.htm?25/2/25635\">",
"     image 9",
"    </a>",
"    ). Once a vegetation has been identified, a series of criteria can be applied to judge prognosis. The use of echocardiography in the evaluation of endocarditis is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20617?source=see_link\">",
"     \"Role of echocardiography in infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Functional mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary myocardial disease or dilated cardiomyopathy (DCM) is universally associated with some degree of mitral regurgitation (usually mild to moderate) through the agency of spherical LV remodeling, which distorts the alignment of the mitral apparatus, dilates the annulus, and decreases the area of valve apposition. Severe mitral regurgitation can occur in DCM but is less common. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    .) The response of mitral regurgitation severity to treatment has been used to guide therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Ischemic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemia as a cause of mitral regurgitation is suggested by the presence of regurgitation in a patient with coronary artery disease, frequently with a previous inferior myocardial infarction or a dilated left ventricle (",
"    <a class=\"graphic graphic_movie graphicRef73594 \" href=\"mobipreview.htm?28/11/28850\">",
"     movie 22",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef52748 \" href=\"mobipreview.htm?24/60/25539\">",
"     movie 23",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef54431 \" href=\"mobipreview.htm?33/59/34740\">",
"     movie 24",
"    </a>",
"    ). On two-dimensional echocardiography, there is shortening of the mitral valve apparatus, resulting in failure of the leaflets to close properly or completely; the leaflets often do not reach the level of the mitral annulus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Patients with ischemic heart disease may also have mitral regurgitation from annular dilatation (functional MR). A three-dimensional echocardiographic study suggested that it may be possible to differentiate ischemic MR from functional MR in dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/33\">",
"     33",
"    </a>",
"    ]. The pattern of mitral valve deformation was asymmetric in the ischemic MR and symmetric in functional MR; in addition, the left ventricular chamber and mitral annulus were less enlarged in ischemic MR. In this review, we have not used the term \"papillary muscle dysfunction\" because we believe it to be anachronistic and uninformative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Rheumatic mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatic mitral regurgitation is often associated with some degree of mitral stenosis, and the valve area is usually sufficiently reduced to alter its echocardiographic appearance and sufficiently narrowed to separate it readily from normal even when stenosis is minimal. The scarring associated with the rheumatic process usually results in characteristic alterations of valve motion (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Mitral stenosis'",
"    </a>",
"    above) on the M-mode echocardiogram.",
"   </p>",
"   <p>",
"    On two-dimensional imaging, failure of coaptation can also be seen during systole on a short axis image; its extent is proportional to the severity of regurgitation. Rheumatic mitral regurgitation is the only form of insufficiency to have been quantitated by failure of coaptation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61901 \" href=\"mobipreview.htm?15/57/16272\">",
"     image 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32409/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10087049\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiography is the primary diagnostic modality for evaluation of mitral valve structure and function. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal mitral valve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mitral valve obstruction is caused chiefly by rheumatic mitral stenosis. Less common causes include left atrial myxoma and other tumors, severe mitral annular calcification, left-sided carcinoid heart disease, and congenital disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13610?source=see_link\">",
"       \"Pathophysiology, clinical features, and evaluation of mitral stenosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=see_link\">",
"       \"Carcinoid heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the presence of characteristic valvular and subvalvular structural changes, severe mitral stenosis is associated with a mean transmitral gradient greater than 10 mmHg, pulmonary artery systolic pressure greater than 50 mmHg, and a mitral valve area less than 1.0 cm",
"      <sup>",
"       2",
"      </sup>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Doppler echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with rheumatic mitral stenosis who are potential candidates for percutaneous mitral balloon valvotomy, echocardiography enables evaluation of the likelihood of procedural success. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Echocardiography in balloon valvuloplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography enables quantification of the severity of mitral regurgitation and identification of causes including mitral valve prolapse, flail mitral leaflet, endocarditis, ischemic heart disease, functional regurgitation caused by a cardiomyopathy, and rheumatic mitral disease. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Abnormalities associated with mitral regurgitation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Mitral valve lesions causing mitral regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/1\">",
"      Edler, I. Ultrasound cardiogram in mitral valve disease. Acta Chir Scand 1956; 111:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/2\">",
"      Edler I. Ultrasoundcardiography in mitral valve stenosis. Am J Cardiol 1967; 19:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/3\">",
"      Schiller NB, Foster E, Redberg RF. Transesophageal echocardiography in the evaluation of mitral regurgitation. The twenty-four signs of severe mitral regurgitation. Cardiol Clin 1993; 11:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/4\">",
"      Gutman J, Wang YS, Wahr D, Schiller NB. Normal left atrial function determined by 2-dimensional echocardiography. Am J Cardiol 1983; 51:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/5\">",
"      Flachskampf FA, Franke A, Job FP, et al. Three-dimensional reconstruction of cardiac structures from transesophageal echocardiography. Am J Card Imaging 1995; 9:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/6\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/7\">",
"      Nichol PM, Gilbert BW, Kisslo JA. Two-dimensional echocardiographic assessment of mitral stenosis. Circulation 1977; 55:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/8\">",
"      Wann LS, Weyman AE, Feigenbaum H, et al. Determination of mitral valve area by cross-sectional echocardiography. Ann Intern Med 1978; 88:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/9\">",
"      Hatle L, Brubakk A, Tromsdal A, Angelsen B. Noninvasive assessment of pressure drop in mitral stenosis by Doppler ultrasound. Br Heart J 1978; 40:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/10\">",
"      Hatle L, Angelsen B, Tromsdal A. Noninvasive assessment of atrioventricular pressure half-time by Doppler ultrasound. Circulation 1979; 60:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/11\">",
"      Tischler MD, Niggel J. Exercise echocardiography in combined mild mitral valve stenosis and regurgitation. Echocardiography 1993; 10:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/12\">",
"      Reis G, Motta MS, Barbosa MM, et al. Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis. J Am Coll Cardiol 2004; 43:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/13\">",
"      Zamorano J, Cordeiro P, Sugeng L, et al. Real-time three-dimensional echocardiography for rheumatic mitral valve stenosis evaluation: an accurate and novel approach. J Am Coll Cardiol 2004; 43:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/14\">",
"      Binder TM, Rosenhek R, Porenta G, et al. Improved assessment of mitral valve stenosis by volumetric real-time three-dimensional echocardiography. J Am Coll Cardiol 2000; 36:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/15\">",
"      Abascal VM, Wilkins GT, O'Shea JP, et al. Prediction of successful outcome in 130 patients undergoing percutaneous balloon mitral valvotomy. Circulation 1990; 82:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/16\">",
"      Wilkins GT, Weyman AE, Abascal VM, et al. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988; 60:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/17\">",
"      Fatkin D, Roy P, Morgan JJ, Feneley MP. Percutaneous balloon mitral valvotomy with the Inoue single-balloon catheter: commissural morphology as a determinant of outcome. J Am Coll Cardiol 1993; 21:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/18\">",
"      Himelman RB, Schiller NB. Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. Am J Cardiol 1989; 63:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/19\">",
"      Himelman RB, Stulbarg MS, Lee E, et al. Noninvasive evaluation of pulmonary artery systolic pressures during dynamic exercise by saline-enhanced Doppler echocardiography. Am Heart J 1990; 119:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/20\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/21\">",
"      Helmcke F, Nanda NC, Hsiung MC, et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation 1987; 75:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/22\">",
"      Utsunomiya T, Doshi R, Patel D, et al. Regurgitant volume estimation in patients with mitral regurgitation: initial studies using color Doppler \"proximal isovelocity surface area\" method. Echocardiography 1992; 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/23\">",
"      Grayburn PA, Fehske W, Omran H, et al. Multiplane transesophageal echocardiographic assessment of mitral regurgitation by Doppler color flow mapping of the vena contracta. Am J Cardiol 1994; 74:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/24\">",
"      Hall SA, Brickner ME, Willett DL, et al. Assessment of mitral regurgitation severity by Doppler color flow mapping of the vena contracta. Circulation 1997; 95:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/25\">",
"      Thomas L, Foster E, Schiller NB. Peak mitral inflow velocity predicts mitral regurgitation severity. J Am Coll Cardiol 1998; 31:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/26\">",
"      Thomas L, Foster E, Hoffman JI, Schiller NB. The Mitral Regurgitation Index: an echocardiographic guide to severity. J Am Coll Cardiol 1999; 33:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/27\">",
"      Avgeropoulou CC, Rahko PS, Patel AK. Reliability of M-mode, two-dimensional and Doppler echocardiography in diagnosing a flail mitral valve leaflet. J Am Soc Echocardiogr 1988; 1:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/28\">",
"      Ogawa S, Mardelli TJ, Hubbard FE. The role of cross-sectional echocardiography in the diagnosis of flail mitral leaflet. Clin Cardiol 1978; 1:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/29\">",
"      Cioffi G, Tarantini L, De Feo S, et al. Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. Eur J Heart Fail 2005; 7:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/30\">",
"      Lancellotti P, G&eacute;rard PL, Pi&eacute;rard LA. Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J 2005; 26:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/31\">",
"      Hayakawa M, Inoh T, Kawanishi H, et al. [Two-dimensional echocardiographic findings of patients with papillary muscle dysfunction]. J Cardiogr 1982; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/32\">",
"      Godley RW, Wann LS, Rogers EW, et al. Incomplete mitral leaflet closure in patients with papillary muscle dysfunction. Circulation 1981; 63:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/33\">",
"      Kwan J, Shiota T, Agler DA, et al. Geometric differences of the mitral apparatus between ischemic and dilated cardiomyopathy with significant mitral regurgitation: real-time three-dimensional echocardiography study. Circulation 2003; 107:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32409/abstract/34\">",
"      Wann LS, Feigenbaum H, Weyman AE, Dillon JC. Cross-sectional echocardiographic detection of rheumatic mitral regurgitation. Am J Cardiol 1978; 41:1258.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5334 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-2ED62E8DE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32409=[""].join("\n");
var outline_f31_41_32409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10087049\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL MITRAL VALVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      M-mode echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Two-dimensional echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Doppler echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MITRAL VALVE LESIONS CAUSING INFLOW OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - M-mode echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Two-dimensional TTE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Three-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Echocardiography in balloon valvuloplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cor triatriatum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Left atrial myxoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ABNORMALITIES ASSOCIATED WITH MITRAL REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Determination of severity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Structural parameters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Color flow Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Pulsed and continuous wave Doppler of mitral inflow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Quantitative parameters of mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Doppler of pulmonary veins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Index of severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MITRAL VALVE LESIONS CAUSING MITRAL REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Flail mitral valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Endocarditis of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Rheumatic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10087049\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5334|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/30/10735\" title=\"diagnostic image 1\">",
"      Short axis LV mitral valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/7/20592\" title=\"diagnostic image 2A\">",
"      2D TTE parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/7/19568\" title=\"diagnostic image 2B\">",
"      Apical 4 chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/11/40115\" title=\"diagnostic image 3\">",
"      Long axis MV annular calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/38/22112\" title=\"diagnostic image 4\">",
"      Apical 4 chamber Ca MV annulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/39/624\" title=\"diagnostic image 5\">",
"      Apical 4 chamber MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/1/21520\" title=\"diagnostic image 6\">",
"      Long axis mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/3/18483\" title=\"diagnostic image 7\">",
"      Color flow Doppler MR I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/35/17970\" title=\"diagnostic image 8\">",
"      CW Doppler pulmonary vein MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/2/25635\" title=\"diagnostic image 9\">",
"      Apical 4 chamber echo vegetations mitral valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/57/16272\" title=\"diagnostic image 10\">",
"      Short axis rheumatic MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5334|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/22/5476\" title=\"figure 1\">",
"      Mitral valve structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/27/6576\" title=\"figure 2\">",
"      Anatomy mitral valve leaflets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/54/38759\" title=\"figure 3\">",
"      M mode mitral valve motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/10/41122\" title=\"figure 4A\">",
"      M mode echo mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/25/29087\" title=\"figure 4B\">",
"      M mode mitral stenosis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/2/16416\" title=\"figure 4C\">",
"      M mode mitral stenosis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/36/14912\" title=\"figure 5A\">",
"      Continuous wave Doppler MV area",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/33/44560\" title=\"figure 5B\">",
"      CW Doppler computer MV area",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/7/35952\" title=\"figure 6A\">",
"      Mitral inflow CW Doppler MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/45/17104\" title=\"figure 6B\">",
"      CW Doppler from LA in MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5334|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/52/32578\" title=\"picture 1\">",
"      M mode phono mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5334|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?30/8/30863\" title=\"movie 1\">",
"      Mitral stenosis M mode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?3/0/3074\" title=\"movie 2\">",
"      Mitral stenosis apical long axis echocardiogram 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?18/60/19393\" title=\"movie 3\">",
"      Mitral stenosis apical long axis echocardiogram 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?7/49/7957\" title=\"movie 4\">",
"      Mitral stenosis 4 chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?19/32/19972\" title=\"movie 5\">",
"      Mitral stenosis parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?10/44/10959\" title=\"movie 6\">",
"      Mitral stenosis pulsed wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?29/43/30399\" title=\"movie 7\">",
"      Mitral stenosis apical long axis color Doppler echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?29/30/30178\" title=\"movie 8\">",
"      Left atrial myxoma 4 chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?3/55/3952\" title=\"movie 9\">",
"      Left atrial myxoma long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?39/46/40673\" title=\"movie 10\">",
"      Left atrial myxoma five chamber echocardiogram 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?28/31/29171\" title=\"movie 11\">",
"      Left atrial myxoma five chamber echocardiogram 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?17/10/17571\" title=\"movie 12\">",
"      Left atrial myxoma small four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?30/49/31504\" title=\"movie 13\">",
"      Mitral valve prolapse M-mode echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?31/23/32115\" title=\"movie 14\">",
"      Mitral valve prolapse four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?23/5/23646\" title=\"movie 15\">",
"      Mitral valve prolapse apical long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?16/31/16884\" title=\"movie 16\">",
"      Echo 4-chamber view MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?8/37/8784\" title=\"movie 17\">",
"      Echo four chamber severe MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?20/12/20672\" title=\"movie 18\">",
"      MR due to mitral valve prolapse four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?17/43/18099\" title=\"movie 19\">",
"      Flail mitral leaflet apical long axis color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?12/21/12628\" title=\"movie 20\">",
"      Flail mitral valve four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?1/25/1427\" title=\"movie 21\">",
"      Mitral valve endocarditis healed parasternal long axis echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?28/11/28850\" title=\"movie 22\">",
"      Echo MR in MI apical long axis color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?24/60/25539\" title=\"movie 23\">",
"      Echo parasternal long axis post MI MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?33/59/34740\" title=\"movie 24\">",
"      Echo MR post MI four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5334|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?9/57/10129\" title=\"waveform 1\">",
"      M mode MV annular calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?5/31/5618\" title=\"waveform 2\">",
"      Doppler transmitral inflow pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?31/45/32470\" title=\"waveform 3\">",
"      Doppler diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?4/59/5048\" title=\"waveform 4\">",
"      Continuous wave Doppler MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?10/37/10835\" title=\"waveform 5\">",
"      M mode mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?12/38/12899\" title=\"waveform 6\">",
"      CW doppler of MR V wave cut",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9705?source=related_link\">",
"      Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37801?source=related_link\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/45/28376?source=related_link\">",
"      Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33497?source=related_link\">",
"      Percutaneous mitral balloon valvotomy for mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35319?source=related_link\">",
"      Protocols for stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/6/11369?source=related_link\">",
"      Role of echocardiography in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23146?source=related_link\">",
"      Three-dimensional echocardiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_41_32410="Medical management of lower extremity chronic venous disease";
var content_f31_41_32410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of lower extremity chronic venous disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/41/32410/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32410/contributors\">",
"     Patrick C Alguire, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32410/contributors\">",
"     Barbara M Mathes, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/41/32410/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32410/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32410/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/41/32410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/41/32410/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/41/32410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous hypertension is associated with morphologic changes in the capillary and lymphatic microcirculation that produce important physiologic changes, which include capillary leak, fibrin deposition, erythrocyte and leukocyte sequestration, thrombocytosis, and inflammation. These processes impair oxygenation of the skin and subcutaneous tissues. The clinical manifestations of severe venous hypertension and tissue hypoxia are edema, hyperpigmentation, subcutaneous fibrosis, and ulcer formation.",
"   </p>",
"   <p>",
"    The medical management of chronic venous disease with and without ulceration is discussed here. The etiology, presentation, and pathophysiology of chronic venous disorders are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/29/11735?source=see_link\">",
"       \"Classification of lower extremity chronic venous disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13592?source=see_link\">",
"       \"Clinical evaluation of lower extremity chronic venous disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43365?source=see_link\">",
"       \"Pathophysiology of chronic venous disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/43/33462?source=see_link\">",
"       \"Diagnostic evaluation of chronic venous insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment goals for patients with chronic venous disease include improvement of symptoms, reduction of edema, treatment of lipodermatosclerosis (",
"    <a class=\"graphic graphic_picture graphicRef65447 \" href=\"mobipreview.htm?11/14/11490\">",
"     picture 1",
"    </a>",
"    ), and healing of ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/1\">",
"     1",
"    </a>",
"    ]. An algorithm for the medical management of venous insufficiency is based upon available data and published recommendations (",
"    <a class=\"graphic graphic_algorithm graphicRef50126 \" href=\"mobipreview.htm?35/19/36159\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapies enhancing venous flow (eg, limb elevation, exercise, and compression therapy) improve oxygen transport to the skin and subcutaneous tissues, decrease edema, and reduce inflammation and can be utilized for any patient with symptoms and signs of chronic venous disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13592?source=see_link\">",
"     \"Clinical evaluation of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'General measures'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'Continuous compression therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with symptoms that are refractory to compression therapy or who are unable to tolerate compression therapy may benefit from systemic therapy. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Systemic agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Dry skin, itching, and eczematous changes are treated with various topical dermatologic agents. Contact dermatitis occurs not infrequently, so avoidance of topical products with common sensitizers is advised. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Skin care'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H33\">",
"     'Contact Dermatitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Venous ulceration is treated with a combination of ulcer wound management and compression therapy in the form of compression stockings or compression bandaging systems. The treatment of chronic venous insufficiency with ulceration requires lifestyle changes to achieve treatment goals. An algorithm for medical management is based upon available data and published recommendations (",
"    <a class=\"graphic graphic_algorithm graphicRef50126 \" href=\"mobipreview.htm?35/19/36159\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Continuous compression therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H28\">",
"     'Ulcer care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Superficial vein ablation has been evaluated both for the treatment of venous ulcers and for prevention of recurrence. Surgery is thought to produce beneficial effects via reduction of venous reflux from the deep to the superficial veins by ablating or removing incompetent superficial veins, thereby modifying the effect of venous hypertension upon the cutaneous tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/3\">",
"     3",
"    </a>",
"    ]. The role of venous ablation therapy in the treatment of lower extremity chronic venous disease with or without ulceration is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13592?source=see_link\">",
"     \"Clinical evaluation of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Leg elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple elevation of the feet to at least heart level for 30 minutes three or four times per day improves cutaneous microcirculation and reduces edema in patients with chronic venous disease. In one study of 15 patients with lipodermatosclerosis, leg elevation resulted in a 41 percent increase in blood flow velocity as measured by Doppler fluximetry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/4\">",
"     4",
"    </a>",
"    ]. Limb elevation also promotes healing of venous ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leg elevation alone may be sufficient to relieve symptoms in patients with mild venous disease, but is usually not adequate in more severe cases. It may also not be practical for some people to elevate their legs several times per day because of the nature of their work. Elevation of the feet below the level of the heart, such as in a lounge chair, is ineffective and should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily walking and simple ankle flexion exercises while seated are inexpensive strategies in the management of chronic venous disease. Several small studies have shown improvement in hemodynamic parameters with simple calf muscle (plantar flexion) exercises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The calf muscle pump is often deficient in patients with chronic venous insufficiency and is believed to contribute to the development and delayed healing of venous ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Moreover, physical activity in patients with chronic venous insufficiency and ulceration tends to be very limited. In one study, 35 percent of the patients did not have a 10 minute walk even once a week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONTINUOUS COMPRESSION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous compression therapy, typically accomplished with prescription graduated compression stockings or compression bandages, is an essential component in the treatment of chronic venous disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic venous insufficiency &mdash; Studies show the benefits of long-term compression therapy (stockings or bandages) in patients with severe chronic venous disease associated with edema or venous stasis ulcers. A systematic review of 39 randomized trials concluded ulcer healing rates are increased when compression therapy is used compared to no compression therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/15\">",
"       15",
"      </a>",
"      ]. Healing rates as high as 97 percent are achieved in patients who are compliant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Superficial reflux and varicose veins &ndash; Graduated compression stockings may be beneficial in managing the symptoms associated with superficial reflux and varicose veins. Little data are available to guide the duration of treatment for these patients. The physiologic benefits of elastic stockings in patients with symptomatic varicose veins are often immediately apparent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]. Clinically, patients experience symptomatic improvement from one to six weeks after initiating therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/20-25\">",
"       20-25",
"      </a>",
"      ]. There are no studies demonstrating that a longer period of therapy further improves physiology. If the patient tolerates wearing the stockings, most patients can determine within a short period of time if their symptoms are sufficiently controlled, or whether to seek additional treatment. In the absence of clinical studies, we prefer a minimum of three months of conservative therapy prior to considering venous ablation therapy. Treatment algorithms in studies comparing various endovenous therapies typically use a threshold of three months of conservative management prior to offering treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/26\">",
"       26",
"      </a>",
"      ]. Furthermore, many insurance companies also use a threshold of three months of conservative management using stockings prior to allowing invasive varicose vein treatments. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34521?source=see_link&amp;anchor=H22#H22\">",
"       \"Overview and management of lower extremity chronic venous disease\", section on 'Management of venous reflux'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism by which compression therapy produces beneficial effects is not clear. In most (but not all) reports, they improve venous hemodynamics by reducing venous reflux, increasing deep venous flow velocity, improving lymphatic flow and cutaneous microcirculation, and decreasing ambulatory venous pressures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/20,27-34\">",
"     20,27-34",
"    </a>",
"    ]. Compression therapy may also alter the expression of certain pro-inflammatory matrix metalloproteinases (MMPs) present in chronic venous ulcers with favorable changes promoting ulcer healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition to generating external pressure, compression that is intermittent also enhances fibrinolysis, a potentially important mechanism in reducing fibrosis and enhancing ulcer healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Intermittent pneumatic compression therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527637549\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cellulitis, if present, is initially treated with limb elevation and systemic antibiotics. Compression therapy is delayed until inflammation and pain subside. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link&amp;anchor=H6#H6\">",
"     \"Cellulitis and erysipelas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to keep in mind that approximately 20 percent of lower extremity ulcers are of mixed venous and arterial origin and therefore confirmation of a purely venous etiology for the ulceration is essential prior to initiating compression therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In patients with non-palpable pulses or risk factors for peripheral artery disease, vascular evaluation including ankle-brachial index should be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/40/19078?source=see_link&amp;anchor=H55267256#H55267256\">",
"     \"Clinical assessment of wounds\", section on 'Differentiation of chronic ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with abnormal ABIs or symptomatic PAD and venous ulcers should be referred to a vascular specialist for evaluation and decision-making regarding wound care. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Indications for Referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Compression therapy is contraindicated in patients found to have moderate to severe peripheral artery disease and used with great caution in patients with mild to moderate peripheral artery disease, as evidenced by an ankle-brachial index &lt;0.9 but &gt;0.6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/40\">",
"     40",
"    </a>",
"    ]. The use of compression therapy in the presence of arterial disease can cause skin necrosis and, in a few instances, has led to amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709635695\">",
"    <span class=\"h2\">",
"     Compression bandages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either elastic or non-elastic compression bandages are used in treating chronic venous insufficiency when there is associated severe edema, weeping, eczema, or ulceration. Compression bandages (multi- or single- component) must be applied by trained personnel and changed depending on the degree of drainage. Methods of compression bandaging including the choice of bandages, placement and care are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/55/9079?source=see_link\">",
"     \"Compression bandaging for chronic venous insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Graduated compression stockings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescription graduated compression stockings provide a pressure gradient across the length of the stocking. The greatest pressure is exerted at the ankle with a gradual decrease in pressure proximally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Compression stocking prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower extremity graduated compression stocking prescriptions vary depending on the symptoms and signs of venous disease and patient factors. The grade of compression, length, and type of stocking must be specified on the prescription (",
"    <a class=\"graphic graphic_table graphicRef74574 \" href=\"mobipreview.htm?36/42/37547\">",
"     table 1",
"    </a>",
"    ). Many compression stockings without elastic are now available; this represents an important advance for those patients with rubber (latex) sensitivity.",
"   </p>",
"   <p>",
"    Although frequently prescribed, there is no evidence that diuretics are beneficial in the management of edema that is due solely to chronic venous insufficiency and their use may result in hypovolemia, orthostasis and prerenal azotemia. Diuretics may be appropriate in selected patients with other conditions known to exacerbate venous insufficiency such as heart failure. We recommend against using diuretics to control edema prior to fitting compression stockings. Instead, the patient should be instructed to schedule a morning appointment shortly after waking to minimize accumulation of edema. If this is not possible, some clinicians and fitting technicians have patient elevate their legs for 30 to 90 minutes prior to leg measurements to get a more accurate fit. Alternatively, if edema is severe, compression bandages can be applied to gradually reduce edema over a period of several weeks prior to fitting compression stockings.",
"   </p>",
"   <p>",
"    Compression stockings should exert a minimum of 20 to 30 mmHg pressure at the ankle to be effective (",
"    <a class=\"graphic graphic_table graphicRef74574 \" href=\"mobipreview.htm?36/42/37547\">",
"     table 1",
"    </a>",
"    ). The white \"anti-embolism\" stockings commonly given to patients in the hospital exert only 8 to 10 mmHg pressure at the ankle, which may be effective for the primary prevention of deep venous thrombosis but is not an adequate treatment of venous insufficiency. A higher grade of compression stockings (30 to 40 mmHg) is prescribed when symptoms and signs are more severe. Higher grade compression garments (eg, 40 to 50 mmHg or 50 to 60 mmHg) are available but are usually reserved for patients with chronic lymphedema or in the management of burn scars. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of lengths of lower extremity graduated compression stockings are available, including knee-high, thigh-high, chaps (unilateral waist high), standard pantyhose, and maternity pantyhose. Knee-high stockings are sufficient for most patients and are generally well tolerated. It is important that these stockings are not pulled up to the popliteal fossa where they can bind and impede venous flow.",
"   </p>",
"   <p>",
"    Thigh high stockings are often prescribed following venous surgery. They are also useful for providing an additional level of support during periods of prolonged travel. It is important to pull these stockings up the thigh adequately so they do not wrinkle when the knee is bent. Otherwise they also can bind in the popliteal space and impede venous flow, causing patient discomfort and limiting compliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/27\">",
"     27",
"    </a>",
"    ]. Thigh high stockings also have a tendency to roll down (in spite of the self adherent band at the level of the thigh).",
"   </p>",
"   <p>",
"    Open toe compression stockings can be useful for patients with foot deformities (bunions, rheumatoid arthritis, diabetes).",
"   </p>",
"   <p>",
"    Some patients do not have the strength or mobility to pull on compression stockings. Alternatives include stockings with a zipper and leggings with Velcro fastening bands. These are custom options and are more expensive. Donning devices, with appropriate instruction, may help many patients apply their stockings (",
"    <a class=\"graphic graphic_figure graphicRef78752 \" href=\"mobipreview.htm?25/58/26528\">",
"     figure 1",
"    </a>",
"    ). Alternately, lower grade compression stockings (&lt;20 mmHg) may still provide a benefit in this situation, given that any level of compression is more beneficial than no compression at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If an ulcer is present, compression stockings can be worn over a simple dressing covering the ulcer, however, compression stockings may be more difficult to apply in this situation. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Ulcer care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Use and care of compression stockings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper measurement and fitting of the stockings, specific patient instruction, and encouragement may enhance compliance with compression stockings.",
"   </p>",
"   <p>",
"    Patients should receive the following instructions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before placement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wash new compression stockings by hand before wearing to reduce some of the initial stiffness and difficulty in application.",
"     </li>",
"     <li>",
"      Compression stockings absorb skin oils and cause the skin to dry out so the skin should be moisturized in the evening just prior to reclining in bed after the stockings are removed.",
"     </li>",
"     <li>",
"      Any ulcer care should be undertaken just prior to placing stockings to avoid the need to remove the stockings later in the day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stockings should be put on in the morning when edema is minimal and after the placement of ulcer dressings, if any. If there will be a delay after rising from bed (eg, shower), it is useful to elevate the legs for twenty to thirty minutes prior to putting on the stockings.",
"     </li>",
"     <li>",
"      Patients should sit in a chair with a firm back support (not on the bed) to lean against while applying the stocking.",
"     </li>",
"     <li>",
"      Stockings can be applied by turning the foot portion of the stocking inside-out down to the heel (",
"      <a class=\"graphic graphic_figure graphicRef78752 \" href=\"mobipreview.htm?25/58/26528\">",
"       figure 1",
"      </a>",
"      ). The foot is slipped into the stretched stocking and pulled onto the foot by its folded edge. Once the stocking is over the heel, the remainder of the stocking can be gathered and progressively turned right-side out and gently worked up the leg. Some manufacturers recommend wearing rubber gloves to help slide the stocking up the leg.",
"     </li>",
"     <li>",
"      Higher grade compression stockings may go on more easily if a light silk hose is worn under the compression garment.",
"     </li>",
"     <li>",
"      A simple device, referred to as a stocking aid or donner, is helpful for patients with limited strength or hand mobility (eg, arthritis) or patients who have difficulty bending over (eg, obesity, spine problems). Different types of donners are available. One type is a wire frame with handles. The stocking is stretched over the frame holding the stocking open permitting easier insertion of the foot. Pulling the handles of the donner facilitates pulling the stocking up the leg (",
"      <a class=\"graphic graphic_figure graphicRef52883 \" href=\"mobipreview.htm?12/50/13088\">",
"       figure 2",
"      </a>",
"      ). Another type of donner is a tube-like sleeve that is placed in the stocking; after the stocking is in place, the tube is collapsed and removed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Care of stockings &ndash; Skin moisturizers and agents used in ulcer care and wound drainage will soil and decrease the longevity of stockings. Stockings should be washed after wearing each day, if possible. Stockings can be hand or machine (delicate cycle) washed with a minimal amount of a mild detergent in warm water and rinsed thoroughly. All hose can be hung up to dry, but stockings with elastic should not be machine dried as the heat will destroy the elastic fibers and the stockings will wear out faster. Hose made of non-elastic fiber can be machine dried with low heat. The purchase of at least two pairs of stockings at a time is beneficial to facilitate the wash and wear cycle. The elasticity of all fabrics diminishes with time and washing. In order to maintain proper compression, ideally, stockings should be replaced every six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Compliance with compression therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While compression stockings have been shown to be beneficial, patient compliance with compression stockings is often poor. Common patient complaints that can lead to noncompliance include itching, tightness, difficulty with application, pins and needles sensation, and rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/44\">",
"     44",
"    </a>",
"    ]. Compression bandaging systems can also be uncomfortable, leading some patients to remove them prematurely.",
"   </p>",
"   <p>",
"    Younger patients are more compliant than older patients and compliance is better in patients with lesser degrees of chronic venous disease (eg, varicose veins) as compared to those with chronic venous insufficiency (severe edema, ulceration). In a prospective trial of younger subjects (mean age 60 years), 76 percent were fully compliant with their compression stockings, 16 percent \"sometimes\" compliant, and only 8 percent never wore their stockings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of 3144 patients newly referred to a tertiary care practice also demonstrated an overall low rate of compliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/46\">",
"     46",
"    </a>",
"    ]. In this study, compliance was better among those with a history of deep venous thrombosis compared to those with no history of deep venous thrombosis (50 versus 35 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INTERMITTENT PNEUMATIC COMPRESSION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard compression stockings may be ineffective or not tolerated in patients with morbid obesity or severe edema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lipodermatosclerosis. Intermittent pneumatic compression (IPC) pumps may be helpful in the initial management of these patients, but should not be used in patients with edema due to heart failure, occlusive arterial disease, or acute cellulitis. IPC is generally prescribed for four hours per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/47\">",
"     47",
"    </a>",
"    ]. A systematic review of randomized trials concluded that there was insufficient evidence on which to make definitive conclusions about the efficacy of IPC pumps in the treatment of venous ulceration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/48\">",
"     48",
"    </a>",
"    ]. They may increase healing when compared to no compression therapy, but the impact on healing when used instead of or added to compression bandaging is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IPC pumps consist of a plastic air cylinder that encases the lower leg and periodically inflates to a preset pressure to compress the leg and then deflates. IPC pumps may consist of a single chamber, or multiple chambers that inflate sequentially from the foot to the knee. Multi chamber IPC pumps are more effective than single chamber systems in clearing venographic dye from the deep venous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SYSTEMIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of systemic agents have been used in the management of chronic venous disease. These include diuretics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , systemic antibiotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , stanazol, escin (horse chestnut seed extract), hydroxyethylrutoside, sulodexide, and prostacyclin analogs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics have no role in the treatment of edema due solely to chronic venous insufficiency; however, diuretics may be prescribed as a treatment for other medical conditions that exacerbate lower extremity edema (eg, heart failure, renal dysfunction) and worsen lower extremity symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30503?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of the treatment of edema in adults\", section on 'General principles of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    may accelerate the healing of chronic venous ulcers and thus is useful in patients who do not have a contraindication to its use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/50\">",
"     50",
"    </a>",
"    ]. Thrombocytosis and increased platelet volume are features associated with chronic venous insufficiency, but the actual role of platelets in the development of venous stasis and ulceration is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a double-blind randomized clinical trial involving 20 patients, 300 mg of enteric coated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    per day significantly improved the number of healed ulcers at four months compared with placebo (38 versus 0 percent, respectively), and increased the number of patients who achieved a significant reduction in ulcer size (52 versus 26 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/50\">",
"     50",
"    </a>",
"    ]. All patients in this study were also treated with compression bandages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Systemic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic antibiotics should be used only in patients who have signs and symptoms of acute cellulitis or a clinically infected ulcer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link&amp;anchor=H6#H6\">",
"     \"Cellulitis and erysipelas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine swabbing of leg ulcers is unnecessary in the absence of signs of infection. Most venous ulcers are heavily contaminated with both gram positive and gram negative bacteria (Staphylococcus, Streptococcus, Escherichia coli, Proteus, Pseudomonas).",
"   </p>",
"   <p>",
"    The routine use of antibiotics in uncomplicated ulcers does not reduce bacterial colonization or improve healing rates, but can cause the emergence of resistant organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. In one study, routinely administered systemic antibiotics were associated with the development of resistant organisms in 94 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , 12 percent treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    , and 4 percent receiving placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic antibiotics are reserved for patients who have one or more of the following signs and symptoms suggesting significant infection:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increase in pain and leg swelling, local heat, and tenderness",
"     </li>",
"     <li>",
"      Increasing erythema of the surrounding skin",
"     </li>",
"     <li>",
"      Lymphangitis (red streaks traversing up the limb)",
"     </li>",
"     <li>",
"      Rapid increase in the size of the ulcer",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of greater than 100,000 bacteria per gram of tissue may impede wound healing. If infection is suspected clinically, the ulcer should be cultured and antibiotics selected based upon the results. The ulcer is irrigated to remove surface debris and then a tissue specimen is obtained by biopsy from the base of the ulcer and sent for culture. Some practitioners inject sterile saline (1 to 2 mL) into the dermis surrounding the ulcer and then quickly withdraw the fluid, which is sent for culture.",
"   </p>",
"   <p>",
"    Empiric treatment pending culture results should target Gram positive and negative organisms, including Pseudomonas. Methicillin resistant Staphylococcus aureus (MRSA) is an important cause of soft tissue infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with rapidly progressing infections, particularly if associated with fever and other signs of systemic toxicity, should be hospitalized and receive intravenous antibiotics with broad coverage. Diabetics are more prone to develop rapidly progressive infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link&amp;anchor=H6#H6\">",
"     \"Cellulitis and erysipelas\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pentoxifylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of trials have studied the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    (varying doses), with or without adjunctive compression therapy, in patients with venous ulcers. A meta-analysis evaluated 11 trials of variable quality; pentoxifylline was significantly more effective for complete or partial ulcer healing than placebo or no treatment (RR 1.7, 95% CI 1.3-2.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/55\">",
"     55",
"    </a>",
"    ]. Pentoxifylline used as an adjunct to compression was more effective than medication without compression. When used without compression, it was more effective than placebo or no treatment at a dose of 800 mg three times a day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/56\">",
"     56",
"    </a>",
"    ]. Gastrointestinal side effects (nausea, indigestion, diarrhea) were relatively common in patients treated with pentoxifylline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Stanozolol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stanozolol (stanazol), an anabolic steroid, stimulates blood fibrinolysis and has been evaluated for the treatment of the more advanced skin changes associated with lipodermatosclerosis. Several randomized trials noted improvement in the area of lipodermatosclerosis, reduced skin thickness and possibly faster ulcer healing rates with stanozolol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Escin (horse chestnut seed extract)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Horse chestnut seed extract (HCE) at a dose of 300 mg (standardized to 50 mg of escin [aescin], the active compound) twice daily may be used in patients unable or unwilling to use compression, or for those in whom compression is contraindicated (eg, occlusive arterial disease). HCE reduces leg volume and edema in patients with chronic venous insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. It can be purchased without a prescription in health food stores, but its purity and standardization cannot be guaranteed.",
"   </p>",
"   <p>",
"    HCE stimulates the release of F series prostaglandins (eg, PGF2-alpha) which induce venoconstriction, decreasing the permeability of vessel walls to low molecular proteins, water, and electrolytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several placebo controlled trials and at least two meta-analyses have concluded that HCE improves symptoms related to chronic venous insufficiency when compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/60,61,63-65\">",
"     60,61,63-65",
"    </a>",
"    ]. In one study, HCE at a dose of 50 mg of escin twice daily not only was superior to placebo, it was equivalent to compression stockings for reducing leg volume and edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/60\">",
"     60",
"    </a>",
"    ]. Adverse effects are usually mild and infrequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hydroxyethylrutoside",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydroxyethylrutoside (HR) is well tolerated and effective at reducing leg volume, edema, and symptoms of chronic venous insufficiency. It has been used in Europe for more than 30 years, but is not available in the United States.",
"   </p>",
"   <p>",
"    Hydroxyethylrutoside (Daflon, Les Laboratories Servier, Gidy, France) is a standard mixture of semisynthetic flavonoids that act mainly upon the endothelium of the microvasculature to reduce permeability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/66\">",
"     66",
"    </a>",
"    ]. The efficacy of HR for the management of symptoms associated with chronic venous insufficiency was analyzed in a meta-analysis of 15 randomized placebo controlled trials involving over 1900 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/67\">",
"     67",
"    </a>",
"    ]. The HR group had a significantly higher response (disappearance of symptoms) in all categories examined, including pain (38 versus 27 percent with placebo), cramps (38 versus 26 percent), tired legs (34 versus 22 percent), swelling (49 versus 35 percent), and restless legs (50 versus 26 percent).",
"   </p>",
"   <p>",
"    In one study, it was found to be superior to horse chestnut seed extract (HCE), with 75 percent of patients achieving a response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/61\">",
"     61",
"    </a>",
"    ]. In a second report, the combined treatment of compression stockings and HR was superior to stockings plus placebo in the reduction of leg volume; similar to HCE, the treatment effect was noted for six weeks after withdrawal of the active drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/68\">",
"     68",
"    </a>",
"    ]. However, the effectiveness of HR for the treatment of venous ulcers has been equivocal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both HCE and HR are well tolerated, even in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/69\">",
"     69",
"    </a>",
"    ], for at least six months; longer follow-up is not available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Sulodexide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulodexide appears to be an effective adjunct to local wound care and dressings in patients with venous ulceration. It is a highly purified glycosaminoglycan that is available in Europe and other parts of the world, but not the United States.",
"   </p>",
"   <p>",
"    A randomized, double-blind trial of 230 patients with venous ulcers of varying size and duration compared the use of sulodexide (60 mg intramuscularly every other day for 20 days, then 50 mg orally twice daily for 70 days) to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/70\">",
"     70",
"    </a>",
"    ]. Patients in both groups also received local wound care and compression bandaging until the ulcers healed. The sulodexide group had a significantly higher healing rate at two and three months compared with placebo (35 versus 21 percent at two months and 52.5 versus 32.7 percent at three months). On intention to treat analysis, this corresponds to five patients that need to be treated with sulodexide to have one additional ulcer healed at three months. Ulcers most likely to heal with sulodexide were smaller than 10 cm2 and of relatively recent onset (up to 12 months). There was no difference in adverse events between the sulodexide and placebo groups.",
"   </p>",
"   <p>",
"    These findings suggest that where available, sulodexide may be an effective adjunct to local wound therapy. The mechanism by which it affects ulcer healing in patients with venous insufficiency is not clear, but may be related to its effects on leukocyte-platelet activation, and its antithrombotic, profibrinolytic, and fibrinogen lowering properties.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prostacyclin analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The synthetic analogue of prostacyclin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    (carboprostacyclin, given parenterally at 0.5 to 2",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per min), is a potent vasodilator that inhibits platelet aggregation and adhesion, increases red blood cell deformability, alters neutrophil function (including free-radical production) and capillary permeability, and may help repair damaged endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/71\">",
"     71",
"    </a>",
"    ]. In a single randomized trial, intravenous infusion of iloprost compared to saline in a three week protocol, increased the rate of ulcer healing, and the percentage of patients with resolution of their lower extremity ulcers (100 versus 84 percent at 150 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/72\">",
"     72",
"    </a>",
"    ]. Intravenous iloprost is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SKIN CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stasis dermatitis manifests as a combination of pruritus, hemosiderin deposition, erythema, and scaling and is often seen with more advanced disease (CEAP 4 or higher). Itching may be intense and sometime blistering and oozing occurs. Proper skin care with skin cleansing and the use of emollients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    barrier preparations help maintain an intact skin barrier. Prevention of dryness and fissuring, and reducing itching and scratching are important to prevent the development of skin ulceration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13592?source=see_link\">",
"     \"Clinical evaluation of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/29/11735?source=see_link\">",
"     \"Classification of lower extremity chronic venous disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contact sensitization occurs more readily in areas of stasis dermatitis. These patients can also develop eczematous reactions in other body areas (auto eczematization or \"id\" reaction). (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Contact Dermatitis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=see_link&amp;anchor=H14#H14\">",
"     \"Contact dermatitis in children\", section on 'Autoeczematization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Skin Cleansing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should gently wash their legs daily using mild non-soap cleansers (eg, Dove&reg;, Olay&reg;, Cetaphil&reg;, Caress&reg;, Neutrogena&reg;) to remove scale, bacteria, and crusts. Products without artificial colors or fragrance may be less irritating, and petrolatum based body washes (eg, Dove&reg;, Olay&reg;, Aveeno&reg;) or in-shower conditioners (eg, Olay&reg;) can minimize the dryness that occurs with daily washing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Emollients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emollients provide a film of oil to lubricate the skin, which limits dryness, itching, and subsequent skin fissuring. Emollients are best applied when the skin is damp (ie, immediately after showering or bathing); they trap water and prevent surface drying. Commonly used ingredients in emollients are petrolatum,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    , and dimethicone silicon oil. Although it is an effective agent, lanolin is associated with skin sensitization in stasis dermatitis, and should be avoided.",
"   </p>",
"   <p>",
"    Examples of effective emollients are Vaseline&reg;, Aquaphor&reg;, Lubriderm&reg;, Cetaphil&reg;, and Aveeno&reg;. Products containing ammonium lactate (Lac-Hydrin&reg;, AmLactin&reg;) can be used when scaling is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Barrier preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical barriers physically block chemical irritants and moisture from contacting the skin and are used to protect the skin from exudative ulcer drainage. They help reduce the itching of dry skin and prevent further skin breakdown.",
"   </p>",
"   <p>",
"    The most common over-the-counter topical barriers contain petrolatum,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    , or both. Some also contain paraffin, or dimethicone or lanolin. Like the emollients, barrier preparations that contain fragrance, preservatives, or other ingredients with irritant or allergic potential (eg, lanolin or fragrances) should be avoided. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Topical agents'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H33\">",
"     'Contact Dermatitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      White petrolatum (Vaseline&reg;) is an effective, inexpensive, and non-sensitizing product. Petrolatum is often the vehicle for the delivery of topical",
"      <strong>",
"       corticosteroids",
"      </strong>",
"      which may be used to treat stasis dermatitis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"       Zinc oxide",
"      </a>",
"      cream, ointment, or paste is also inexpensive and provides an impermeable barrier to irritants. It also has a drying effect and, while useful to protect the skin surrounding an ulcer, it may cause excessive drying if generally applied to the extremity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific symptoms of stasis dermatitis including erythema, inflammation, pruritus, and vesicle formation may require treatment with group III or IV (mid-potency) topical corticosteroids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=see_link\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The affected skin in chronic venous insufficiency is easily sensitized, and contact sensitization to the topical corticosteroids themselves can occur in this setting. Ointment preparations are preferred because petrolatum-based vehicles have fewer additives like preservatives and emulsifiers that can irritate or sensitize the skin.",
"   </p>",
"   <p>",
"    Failure of dermatitis to improve or the development of increased redness, blisters, increased itching, eczematous changes and oozing skin, or appearance of dermatitis in other body areas are indicators that allergic contact dermatitis is present. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Contact Dermatitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ULCER CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Ulcer debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound debridement is an essential component of the management of venous ulcers. The presence of devitalized tissue increases the potential for local bacterial infection and sepsis, reduces wound healing rates, and reduces the effectiveness of topical therapies and systemic antibiotics. Removal of necrotic tissue and fibrinous debris in venous ulcers aids in formation of healthy granulation tissue and enhances reepithelialization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37064?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of pressure ulcers\", section on 'Debridement'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H30\">",
"     'Topical agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A moist environment is essential for wound healing; however, ulcer healing rates are not improved with the use of most topical agents such as topical antiseptics, topical antibiotics, debriding enzymes and growth factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/73\">",
"     73",
"    </a>",
"    ]. Many topically applied products are irritating and can cause contact sensitization, or are cytotoxic, resulting in delayed healing. Honey, a folk remedy, does not improve ulcer healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Contact Dermatitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10964?source=see_link\">",
"       Silver sulfadiazine",
"      </a>",
"      &ndash; Silver",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      (eg, Silvadene) is a topical antiseptic cream with a long tradition in the treatment of cutaneous wounds including burns, partial thickness wounds, and skin graft donor sites. It releases silver ions in concentrations that are toxic to bacteria and inhibits the growth in vitro of nearly all pathogenic bacteria and fungi, including some species resistant to sulfonamides.",
"      <br/>",
"      <br/>",
"      Silver sulfadiazine has been used in contaminated or infected wounds; however, it is messy to use and forms a pseudo eschar requiring removal prior to redressing the wound, and may stain the skin. To address some of these issues, silver impregnated dressings have become more popular than silver cream preparations due to their absorbent qualities and ease of use. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Ulcer dressings'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Adverse effects associated with the use of silver sulfadiazine include induction of bacterial resistance and hypersensitivity, either as contact dermatitis or major allergic reaction (sulfa allergy). While little silver is absorbed through the wound, systemic toxicity is a theoretical concern in very large open wounds (eg, major burns) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cadexomer iodine",
"      </strong>",
"      &ndash; A systematic review found some evidence that topical application of cadexomer iodine enhances ulcer healing rates compared to standard care (with and without compression) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/73\">",
"       73",
"      </a>",
"      ]. The treatment regimen was complex and it is unclear if the results are generalizable to most clinical settings. Iodine-induced hyperthyroidism has been documented with use of cadexomer iodine for leg ulcers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other antiseptic agents",
"      </strong>",
"      &ndash; Studies of other topically applied antiseptics, including",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      , and sodium hypochlorite were of poor quality and definitive conclusions about their effectiveness cannot be made [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/73\">",
"       73",
"      </a>",
"      ]. These topical antiseptics in vitro and in animal studies have cellular toxicities that exceed their bactericidal activities. For this reason, they should not be used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/77-79\">",
"       77-79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Enzymatic agents",
"      </strong>",
"      &ndash; The accumulation of fibrin may delay the healing of chronic ulcers by preventing granulation and epithelialization. Several enzyme debriding agents are available, including krill enzymes (from antarctic shrimp). These consist of natural endopeptidases and exopeptidases capable of breaking down proteinaceous substances to soluble free amino acids. In one randomized trial, krill enzyme treatment significantly diminished necrotic area in venous ulcers by 53 percent, no reduction was observed in the group receiving usual care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/80\">",
"       80",
"      </a>",
"      ]. Aside from this single trial, there are no other published data to support the use of enzymatic debriding agents in treatment of venous stasis ulcers.",
"     </li>",
"     <li>",
"      <strong>",
"       Growth factors",
"      </strong>",
"      &ndash; Several growth factors play a role in wound healing, including platelet derived growth factor, epidermal growth factor, fibroblast growth factors, transforming growth factors, and insulin-like growth factors. A few well controlled randomized trials have assessed the use of growth factors in the healing of a variety of chronic diabetic and pressure ulcers and reported conflicting results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/81-84\">",
"       81-84",
"      </a>",
"      ]. In a study of chronic venous ulcers, topical application of human recombinant epidermal growth factor caused a greater reduction in ulcer size compared with placebo (7 versus 3 percent reduction) and resulted in a larger number of healed ulcers (35 versus 11 percent); this trial was small and the results were not statistically significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/85\">",
"       85",
"      </a>",
"      ]. Epithelialization was not significantly affected.",
"      <br/>",
"      <br/>",
"      Intradermal injections of granulocyte-macrophage colony stimulating factor (GM-CSF) appear to promote healing of chronic leg ulcers including venous ulcers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]. A randomized trial in 60 patients with venous ulcers found that four weekly injections with GM-CSF 200 mcg or 400 mcg led to significantly higher rates of healing compared with placebo at 13 weeks (57, 61, and 19 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/87\">",
"       87",
"      </a>",
"      ]. The use of intradermal GM-CSF is limited by the pain from the injections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Ulcer dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dressings are an important component of ulcer care. Dressings control exudate, maintain moisture balance, control odor, and help control pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/2\">",
"     2",
"    </a>",
"    ]. Dressings also maintain an environment that facilitates epithelialization and speeds ulcer healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/88\">",
"     88",
"    </a>",
"    ]. Options for dressing venous ulcerations include semipermeable adhesive films, simple nonadherent dressings, paraffin gauze, hydrogels, hydrocolloids, alginates and silver impregnated dressings or foams.",
"   </p>",
"   <p>",
"    Although the utility of dressings to treat ulcers in general is clear, the specific dressing used does not significantly affect ulcer healing when compression therapy is also used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of 42 randomized trials evaluating the efficacy of various venous ulcer dressings including hydrocolloids, foams, alginates and hydrogels, but not silver, found no evidence to support one dressing type over another [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review of randomized trials evaluated various silver-containing dressings in the treatment of venous ulcers; none of the trials identified were of high quality and a variety of dressings were used as controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/91\">",
"       91",
"      </a>",
"      ]. A pooled analysis found evidence for improved wound healing based on wound size reduction but no significant differences in rates of wound healing or completion of healing. In other trials of wound healing, in general, the use of silver dressings was associated with significantly decreased odor and leakage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative advantages or disadvantages of the different dressing types depend upon ulcer characteristics, frequency of dressing changes and cost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/93\">",
"     93",
"    </a>",
"    ]. The type of dressing used can be tailored to the characteristics of the ulcer. Dressings are characterized by their composition and properties (eg, adherence, absorbency, conformability) (",
"    <a class=\"graphic graphic_table graphicRef60931 \" href=\"mobipreview.htm?31/53/32604\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. In practice, several different dressings are used during the course of caring for a venous ulcer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occlusive dressings may be fully occlusive (impermeable to gases and fluids) or semi-permeable (impermeable to fluids and partially permeable to gases like oxygen and water vapor). Occlusive dressings speed reepithelialization, stimulate collagen synthesis, and create a hypoxic environment at the wound bed that encourages angiogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/97\">",
"       97",
"      </a>",
"      ]. Infection rates with occlusive dressings are lower than the rate of infection in general wound care. This may be due to several factors including effective barrier protection and reducing local pH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/98\">",
"       98",
"      </a>",
"      ]. Patents prefer occlusive hydrocolloid dressings due to their ease of application and associated reduction of pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/99-103\">",
"       99-103",
"      </a>",
"      ]. Occlusive hydrocolloid dressings can be changed by the patient every five to seven days at home.",
"     </li>",
"     <li>",
"      Low-adherent gauze dressings require daily or more frequent dressing changes and drainage and odor can be problematic. These dressings are inexpensive.",
"     </li>",
"     <li>",
"      Hydrogels and alginate dressings are highly absorbent and well suited to heavily exudative ulcers, while hydrocolloids can help with wound debridement and also provide skin barrier protection from wound exudates.",
"     </li>",
"     <li>",
"      Silver has been incorporated into various dressing materials as nanocrystalline particles of silver, silver ions, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10964?source=see_link\">",
"       silver sulfadiazine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/104\">",
"       104",
"      </a>",
"      ]. A decrease in wound bacterial counts is associated with their use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/94\">",
"       94",
"      </a>",
"      ]. These agents release higher levels of silver than silver",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      cream; silver in high concentrations is cytotoxic and can impair wound healing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/105\">",
"       105",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Topical agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Skin grafting and human skin equivalents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled surgical trials and expert opinion support the role of skin grafting for very large venous ulcers or for ulcers present for more than 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/88\">",
"     88",
"    </a>",
"    ]. A systematic review of clinical trials determined that bilayer artificial skin in conjunction with compression bandages may increase ulcer healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/106\">",
"     106",
"    </a>",
"    ]. Human skin equivalents should not be thought of as an alternative to initial compression therapy for venous ulcers, but may be considered in patients who do not respond to compression therapy.",
"   </p>",
"   <p>",
"    Several human skin equivalents created from human epidermal keratinocytes, human dermal fibroblasts, and connective tissue proteins are available for the treatment of venous leg ulcers (eg, Apligraf&reg;, Dermagraft&reg;, Integra&reg;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. The graft is fairly easily applied in an outpatient setting.",
"   </p>",
"   <p>",
"    In a study of 293 patients with venous ulcers, compression therapy alone was compared with compression therapy plus treatment with a human skin equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/110\">",
"     110",
"    </a>",
"    ]. The latter group demonstrated significantly improved wound healing as measured by the percentage of patients healed at six months (63 versus 49 percent) and the median time to wound closure (61 versus 181 days). In addition, the human skin equivalent was superior to compression therapy alone for healing larger (&gt;1 cm2) ulcers, deeper ulcers and ulcers of more than six months duration. Adverse events were similar in both groups, the most common being wound infection, cellulitis and pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     CONTACT DERMATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact dermatitis in chronic venous insufficiency is common and may be difficult to diagnose without a high index of suspicion since it often mimics stasis dermatitis or cellulitis. Symptoms include redness, pruritus, and vesicle or bullae formation. The patient with contact dermatitis typically does not typically experience a dramatic clinical worsening, but rather a failure to improve with treatment. Some patients develop an eczematous rash in other areas of the body, a form of \"id\" of auto-eczematous reaction. Contact dermatitis may also be a direct trigger to development of an ulcer in patients with venous insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/111\">",
"     111",
"    </a>",
"    ]. The routine use of systemic or topical antibiotics may also increase the incidence of contact dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=see_link&amp;anchor=H14#H14\">",
"     \"Contact dermatitis in children\", section on 'Autoeczematization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a community sample of patients with venous insufficiency, 51 percent of the subjects had positive skin patch tests consistent with contact dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/112\">",
"     112",
"    </a>",
"    ]. Of those patients with a positive patch test, 87 percent were allergic to components of their stasis ulcer treatment. Contact sensitivity was more common in patients with stasis dermatitis (62 versus 38 percent).",
"   </p>",
"   <p>",
"    Allergic contact dermatitis can develop from sensitization to a variety of products used in the treatment of stasis dermatitis and venous ulceration including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emollients or moisturizers. These contain ingredients that are some of the most common sensitizers (lanolin, parabens and wool wax, fragrances, preservatives)",
"     </li>",
"     <li>",
"      Topical antibiotics (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10964?source=see_link\">",
"       silver sulfadiazine",
"      </a>",
"      ). More than 30 percent of patients develop contact dermatitis to neomycin and 13 percent to bacitracin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/113,114\">",
"       113,114",
"      </a>",
"      ]. Silver",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      is also a skin sensitizer; in one randomized trial, 13 percent of the patients in the treatment arm were forced to drop out because of skin irritation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nickel (tubes that topical products are contained in)",
"     </li>",
"     <li>",
"      Topical corticosteroids. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Skin care'",
"      </a>",
"      above.) Sensitization to topical corticosteroids is not uncommon and can be challenging to diagnose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/116,117\">",
"       116,117",
"      </a>",
"      ]. It should be suspected in any patient with a clinical diagnosis of contact dermatitis who fails to improve or worsens following appropriate treatment with topical corticosteroids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary therapy for contact dermatitis is avoidance. Minor reactions may be treated with emollients and topical corticosteroids (steroid induced reactions) preferably in a petrolatum vehicle as to avoid further reactions. Patch testing may be needed to determine the culprit agents, and a short course of systemic glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) may be necessary to treat more severe reactions and reactions to topical corticosteroids. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Topical agents'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of dermatitis\", section on 'Contact dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     ULCER HEALING AND RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continued use of graduated compression stockings after ulcer healing reduces recurrence and patients should be offered the strongest compression (up to 40 mmHg) (",
"    <a class=\"graphic graphic_table graphicRef74574 \" href=\"mobipreview.htm?36/42/37547\">",
"     table 1",
"    </a>",
"    ) with which they can comply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/48,118\">",
"     48,118",
"    </a>",
"    ]. In one study with 36 months follow-up, ulcers recurred in 100 percent of patients who were noncompliant versus 16 percent in those who were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ulcers that persist (present for more than six months) or who have recurrent ulcers should undergo venous duplex ultrasound to identify segments of venous incompetence amenable to vein ablation therapies. Patients have improved ulcer healing and lower rates of recurrence following venous ablation therapies with primary venous etiologies achieving more benefit compared with secondary etiologies (ie, postthrombotic) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34521?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview and management of lower extremity chronic venous disease\", section on 'Advanced venous disease (C3-6)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate blood supply to a wound due to arterial disease is a far more common cause of nonhealing ulcers than inadequate ulcer care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/38,39,93\">",
"     38,39,93",
"    </a>",
"    ]. Subspecialist referral is recommended for the following problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/41/32410/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arterial insufficiency",
"     </li>",
"     <li>",
"      Nonhealing ulcers",
"     </li>",
"     <li>",
"      Ulcer recurrence",
"     </li>",
"     <li>",
"      Persistent stasis dermatitis",
"     </li>",
"     <li>",
"      Suspected contact dermatitis",
"     </li>",
"     <li>",
"      Diagnostic uncertainty",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     COST OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Representative charges for compression stockings, intermittent pneumatic compression, ulcer dressings and skin graft equivalents are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef81825 \" href=\"mobipreview.htm?11/60/12236\">",
"     table 4",
"    </a>",
"    ). Medicare covers some of the cost of compression hose of at least 30 to 40 mmHg. Medicare will provide partial reimbursement for dressings and home IPC pumping if applied or supervised by a home visiting nurse, or if prescribed in a hospital or nursing home setting. Properly performed studies evaluating the cost-effectiveness of various treatment options are not currently available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/47/41714?source=see_link\">",
"       \"Patient information: Varicose veins and other vein disease in the legs (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/17/35091?source=see_link\">",
"       \"Patient information: Chronic venous disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic venous disorders are common. Symptoms include pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower extremity heaviness that typically worsen as the day progresses. Clinical signs include mild venous dilation, varicose veins, swelling, skin changes or ulceration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13592?source=see_link\">",
"     \"Clinical evaluation of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients with chronic venous symptoms, we suggest leg elevation (when possible), leg exercises (ankle flexion, walking) to increase calf muscle strength, and graduated compression stockings (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General measures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Continuous compression therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intermittent pneumatic compression therapy is an alternative form of compression that may be useful for patients for whom standard compression stockings may be ineffective or not tolerated (eg, morbid obesity, severe edema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lipodermatosclerosis). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Intermittent pneumatic compression therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are unable to tolerate, are not compliant, or in whom compression therapy is contraindicated (eg, occlusive arterial disease), we suggest horse chestnut seed extract&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A typical dose is 300 mg (standardized to 50 mg of escin) twice daily. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Escin (horse chestnut seed extract)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dry skin, itching and eczematous changes are treated with moisturizers and, if needed, a mid - potency topical corticosteroid. We suggest avoiding topical products with common sensitizers (eg, lanolin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      , nickel) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Skin care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Contact Dermatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Venous ulceration is managed with wound debridement as needed, barrier creams to protect adjacent skin and wound dressings tailored to the environment of the wound (eg, absorbent dressings for weeping wounds). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Ulcer care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical antibiotics, debriding enzymes, growth factors, and honey are",
"      <strong>",
"       not",
"      </strong>",
"      effective in the management of venous ulceration. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Topical agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When venous insufficiency is associated severe edema, weeping, eczema or ulceration, either elastic or non-elastic compression bandages are used. For these patients, we suggest multilayered compression bandages rather than single layer bandages (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, multilayered compression bandages are more costly. (See",
"      <a class=\"local\" href=\"#H709635695\">",
"       'Compression bandages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy for patients with venous ulceration (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Aspirin appears to accelerate the healing of chronic venous ulcers. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with slowly healing ulcers, persistent dermatitis or resistant or recurrent cellulitis should be referred to the appropriate subspecialist (",
"      <a class=\"graphic graphic_algorithm graphicRef50126 \" href=\"mobipreview.htm?35/19/36159\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Contact Dermatitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35\">",
"       'Indications for Referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/1\">",
"      Consensus paper on venous leg ulcer. The Alexander House Group. J Dermatol Surg Oncol 1992; 18:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/2\">",
"      Douglas WS, Simpson NB. Guidelines for the management of chronic venous leg ulceration. Report of a multidisciplinary workshop. British Association of Dermatologists and the Research Unit of the Royal College of Physicians. Br J Dermatol 1995; 132:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/3\">",
"      Stacey MC, Burnand KG, Layer GT, Pattison M. Calf pump function in patients with healed venous ulcers is not improved by surgery to the communicating veins or by elastic stockings. Br J Surg 1988; 75:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/4\">",
"      Myers MB, Cherry G, Heimburger S, et al. The effect of edema and external pressure on wound healing. Arch Surg 1967; 94:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/5\">",
"      Abu-Own A, Scurr JH, Coleridge Smith PD. Effect of leg elevation on the skin microcirculation in chronic venous insufficiency. J Vasc Surg 1994; 20:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/6\">",
"      Burnand KG, O'Donnell TF Jr, Thomas ML, Browse NL. The relative importance of incompetent communicating veins in the production of varicose veins and venous ulcers. Surgery 1977; 82:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/7\">",
"      Padberg FT Jr, Johnston MV, Sisto SA. Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial. J Vasc Surg 2004; 39:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/8\">",
"      Yang D, Vandongen YK, Stacey MC. Changes in calf muscle function in chronic venous disease. Cardiovasc Surg 1999; 7:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/9\">",
"      Kan YM, Delis KT. Hemodynamic effects of supervised calf muscle exercise in patients with venous leg ulceration: a prospective controlled study. Arch Surg 2001; 136:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/10\">",
"      Milic DJ, Zivic SS, Bogdanovic DC, et al. Risk factors related to the failure of venous leg ulcers to heal with compression treatment. J Vasc Surg 2009; 49:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/11\">",
"      Simka M. Calf muscle pump impairment and delayed healing of venous leg ulcers: air plethysmographic findings. J Dermatol 2007; 34:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/12\">",
"      Araki CT, Back TL, Padberg FT, et al. The significance of calf muscle pump function in venous ulceration. J Vasc Surg 1994; 20:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/13\">",
"      Heinen MM, van der Vleuten C, de Rooij MJ, et al. Physical activity and adherence to compression therapy in patients with venous leg ulcers. Arch Dermatol 2007; 143:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/14\">",
"      de Araujo T, Valencia I, Federman DG, Kirsner RS. Managing the patient with venous ulcers. Ann Intern Med 2003; 138:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/15\">",
"      O'Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. Cochrane Database Syst Rev 2009; :CD000265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/16\">",
"      Mayberry JC, Moneta GL, Taylor LM Jr, Porter JM. Fifteen-year results of ambulatory compression therapy for chronic venous ulcers. Surgery 1991; 109:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/17\">",
"      Norgren L. Elastic compression stockings--an evaluation with foot volumetry, strain-gauge plethysmography and photoplethysmography. Acta Chir Scand 1988; 154:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/18\">",
"      Norris CS, Turley G, Barnes RW. Noninvasive quantification of ambulatory venous hemodynamics during elastic compressive therapy. Angiology 1984; 35:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/19\">",
"      Labropoulos N, Leon M, Volteas N, Nicolaides AN. Acute and long-term effect of elastic stockings in patients with varicose veins. Int Angiol 1994; 13:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/20\">",
"      Jones NA, Webb PJ, Rees RI, Kakkar VV. A physiological study of elastic compression stockings in venous disorders of the leg. Br J Surg 1980; 67:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/21\">",
"      Kakkar VV. A physiological study of elastic compression stockings in venous disorders of the leg. Phlebologie 1982; 35:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/22\">",
"      Pierson S, Pierson D, Swallow R, Johnson G Jr. Efficacy of graded elastic compression in the lower leg. JAMA 1983; 249:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/23\">",
"      Szendro G, Veller M, Fisher C, et al. The effect of elastic compression on the venous tone in patients with varicose veins. Vasa 1992; 21:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/24\">",
"      Leon M, Volteas N, Labropoulos N, et al. The effect of elastic stockings on the elasticity of varicose veins. Int Angiol 1993; 12:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/25\">",
"      Weiss RA, Duffy D. Clinical benefits of lightweight compression: reduction of venous-related symptoms by ready-to-wear lightweight gradient compression hosiery. Dermatol Surg 1999; 25:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/26\">",
"      Lawrence PF, Chandra A, Wu M, et al. Classification of proximal endovenous closure levels and treatment algorithm. J Vasc Surg 2010; 52:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/27\">",
"      Partsch H. Compression therapy of the legs. A review. J Dermatol Surg Oncol 1991; 17:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/28\">",
"      Somerville JJ, Brow GO, Byrne PJ, et al. The effect of elastic stockings on superficial venous pressures in patients with venous insufficiency. Br J Surg 1974; 61:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/29\">",
"      O'Donnell TF Jr, Rosenthal DA, Callow AD, Ledig BL. Effect of elastic compression on venous hemodynamics in postphlebitic limbs. JAMA 1979; 242:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/30\">",
"      Mayberry JC, Moneta GL, DeFrang RD, Porter JM. The influence of elastic compression stockings on deep venous hemodynamics. J Vasc Surg 1991; 13:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/31\">",
"      Nehler MR, Moneta GL, Woodard DM, et al. Perimalleolar subcutaneous tissue pressure effects of elastic compression stockings. J Vasc Surg 1993; 18:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/32\">",
"      Christopoulos D, Nicolaides AN, Szendro G. Venous reflux: quantification and correlation with the clinical severity of chronic venous disease. Br J Surg 1988; 75:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/33\">",
"      Abu-Own A, Shami SK, Chittenden SJ, et al. Microangiopathy of the skin and the effect of leg compression in patients with chronic venous insufficiency. J Vasc Surg 1994; 19:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/34\">",
"      Gj&ouml;res JE, Thulesius O. Compression treatment in venous insufficiency evaluated with foot volumetry. Vasa 1977; 6:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/35\">",
"      Beidler SK, Douillet CD, Berndt DF, et al. Multiplexed analysis of matrix metalloproteinases in leg ulcer tissue of patients with chronic venous insufficiency before and after compression therapy. Wound Repair Regen 2008; 16:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/36\">",
"      Allenby F, Boardman L, Pflug JJ, Calnan JS. Effects of external pneumatic intermittent compression on fibrinolysis in man. Lancet 1973; 2:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/37\">",
"      Tarnay TJ, Rohr PR, Davidson AG, et al. Pneumatic calf compression, fibrinolysis, and the prevention of deep venous thrombosis. Surgery 1980; 88:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/38\">",
"      Harding KG. Leg ulcers. J R Soc Med 1991; 84:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/39\">",
"      Baker SR, Stacey MC, Singh G, et al. Aetiology of chronic leg ulcers. Eur J Vasc Surg 1992; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/40\">",
"      Barr DM. The Unna's boot as a treatment for venous ulcers. Nurse Pract 1996; 21:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/41\">",
"      Callam MJ, Ruckley CV, Dale JJ, Harper DR. Hazards of compression treatment of the leg: an estimate from Scottish surgeons. Br Med J (Clin Res Ed) 1987; 295:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/42\">",
"      London NJ, Donnelly R. ABC of arterial and venous disease. Ulcerated lower limb. BMJ 2000; 320:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/43\">",
"      Choucair M, Phillips TJ. Compression therapy. Dermatol Surg 1998; 24:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/44\">",
"      Franks PJ, Oldroyd MI, Dickson D, et al. Risk factors for leg ulcer recurrence: a randomized trial of two types of compression stocking. Age Ageing 1995; 24:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/45\">",
"      Brandjes DP, B&uuml;ller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/46\">",
"      Raju S, Hollis K, Neglen P. Use of compression stockings in chronic venous disease: patient compliance and efficacy. Ann Vasc Surg 2007; 21:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/47\">",
"      Smith PC, Sarin S, Hasty J, Scurr JH. Sequential gradient pneumatic compression enhances venous ulcer healing: a randomized trial. Surgery 1990; 108:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/48\">",
"      Nelson EA, Mani R, Vowden K. Intermittent pneumatic compression for treating venous leg ulcers. Cochrane Database Syst Rev 2008; :CD001899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/49\">",
"      Nicolaides AN, Fernandes e Fernandes J, Pollock AV. Intermittent sequential pneumatic compression of the legs in the prevention of venous stasis and postoperative deep venous thrombosis. Surgery 1980; 87:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/50\">",
"      Layton AM, Ibbotson SH, Davies JA, Goodfield MJ. Randomised trial of oral aspirin for chronic venous leg ulcers. Lancet 1994; 344:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/51\">",
"      Goodfield MJ. A relative thrombocytosis and elevated mean platelet volume are features of gravitational disease. Br J Dermatol 1986; 115:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/52\">",
"      Huovinen S, Kotilainen P, J&auml;rvinen H, et al. Comparison of ciprofloxacin or trimethoprim therapy for venous leg ulcers: results of a pilot study. J Am Acad Dermatol 1994; 31:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/53\">",
"      Lineaweaver W, Howard R, Soucy D, et al. Topical antimicrobial toxicity. Arch Surg 1985; 120:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/54\">",
"      Alinovi A, Bassissi P, Pini M. Systemic administration of antibiotics in the management of venous ulcers. A randomized clinical trial. J Am Acad Dermatol 1986; 15:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/55\">",
"      Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev 2012; 12:CD001733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/56\">",
"      Falanga V, Fujitani RM, Diaz C, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 1999; 7:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/57\">",
"      Burnand K, Clemenson G, Morland M, et al. Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression. Br Med J 1980; 280:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/58\">",
"      McMullin GM, Watkin GT, Coleridge Smith PD, Scurr JH. Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency. Aust N Z J Surg 1991; 61:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/59\">",
"      Heller M, Soldano AC. Sarcoidosis with subcutaneous lesions. Dermatol Online J 2008; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/60\">",
"      Diehm C, Trampisch HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996; 347:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/61\">",
"      Rehn D, Unkauf M, Klein P, et al. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency. Arzneimittelforschung 1996; 46:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/62\">",
"      Longiave D, Omini C, Nicosia S, Berti F. The mode of action of aescin on isolated veins: relationship with PGF2 alpha. Pharmacol Res Commun 1978; 10:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/63\">",
"      Pittler MH, Ernst E. Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. Arch Dermatol 1998; 134:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/64\">",
"      Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2006; :CD003230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/65\">",
"      Siebert U, Brach M, Sroczynski G, Berla K. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. Int Angiol 2002; 21:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/66\">",
"      Wadworth AN, Faulds D. Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs 1992; 44:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/67\">",
"      Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 1994; 23:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/68\">",
"      Unkauf M, Rehn D, Klinger J, et al. Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittelforschung 1996; 46:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/69\">",
"      MacLennan WJ, Wilson J, Rattenhuber V, et al. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology 1994; 40:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/70\">",
"      Coccheri S, Scondotto G, Agnelli G, et al. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002; 87:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/71\">",
"      Lindemann S, Gierer C, Darius H. Prostacyclin inhibits adhesion of polymorphonuclear leukocytes to human vascular endothelial cells due to adhesion molecule independent regulatory mechanisms. Basic Res Cardiol 2003; 98:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/72\">",
"      Ferrara F, Meli F, Raimondi F, et al. The treatment of venous leg ulcers: a new therapeutic use of iloprost. Ann Surg 2007; 246:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/73\">",
"      O'Meara S, Al-Kurdi D, Ovington LG. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database Syst Rev 2008; :CD003557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/74\">",
"      Jull AB, Rodgers A, Walker N. Honey as a topical treatment for wounds. Cochrane Database Syst Rev 2008; :CD005083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/75\">",
"      Lansdown AB, Williams A, Chandler S, Benfield S. Silver absorption and antibacterial efficacy of silver dressings. J Wound Care 2005; 14:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/76\">",
"      Michanek A, Hansson C, Berg G, M&aring;nesk&ouml;ld-Claes A. [Iodine-induced hyperthyroidism after cadexomer iodine treatment of leg ulcers]. Lakartidningen 1998; 95:5755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/77\">",
"      Geronemus RG, Mertz PM, Eaglstein WH. Wound healing. The effects of topical antimicrobial agents. Arch Dermatol 1979; 115:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/78\">",
"      Kjolseth D, Frank JM, Barker JH, et al. Comparison of the effects of commonly used wound agents on epithelialization and neovascularization. J Am Coll Surg 1994; 179:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/79\">",
"      Foresman, PA, Payne, DS, Becker, D, et al. A relative toxicity index for wound cleansers. Wounds 1993; 5:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/80\">",
"      Westerhof W, van Ginkel CJ, Cohen EB, Mekkes JR. Prospective randomized study comparing the debriding effect of krill enzymes and a non-enzymatic treatment in venous leg ulcers. Dermatologica 1990; 181:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/81\">",
"      Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995; 21:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/82\">",
"      Robson MC, Phillips LG, Thomason A, et al. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992; 339:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/83\">",
"      Mustoe TA, Cutler NR, Allman RM, et al. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg 1994; 129:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/84\">",
"      Richard JL, Parer-Richard C, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 1995; 18:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/85\">",
"      Falanga V, Eaglstein WH, Bucalo B, et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992; 18:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/86\">",
"      Marques da Costa R, Jesus FM, Aniceto C, Mendes M. Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcers. Am J Surg 1997; 173:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/87\">",
"      Da Costa RM, Ribeiro Jesus FM, Aniceto C, Mendes M. Randomized, double-blind, placebo-controlled, dose- ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers. Wound Repair Regen 1999; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/88\">",
"      WINTER GD. Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature 1962; 193:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/89\">",
"      O'Donnell TF Jr, Lau J. A systematic review of randomized controlled trials of wound dressings for chronic venous ulcer. J Vasc Surg 2006; 44:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/90\">",
"      Palfreyman SJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers. Cochrane Database Syst Rev 2006; :CD001103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/91\">",
"      Carter MJ, Tingley-Kelley K, Warriner RA 3rd. Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: a systematic review and meta-analysis. J Am Acad Dermatol 2010; 63:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/92\">",
"      Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected wounds. Cochrane Database Syst Rev 2007; :CD005486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/93\">",
"      Ryan TJ. Wound dressing. Dermatol Clin 1993; 11:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/94\">",
"      Sibbald RG, Contreras-Ruiz J, Coutts P, et al. Bacteriology, inflammation, and healing: a study of nanocrystalline silver dressings in chronic venous leg ulcers. Adv Skin Wound Care 2007; 20:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/95\">",
"      Moore RA, Liedl DA, Jenkins S, Andrews KL. Using a silver-coated polymeric substrate for the management of chronic ulcerations: the initial Mayo Clinic experience. Adv Skin Wound Care 2008; 21:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/96\">",
"      Local applications to wounds--II. Dressings for wounds and ulcers. Drug Ther Bull 1991; 29:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/97\">",
"      Katz S, McGinley K, Leyden JJ. Semipermeable occlusive dressings. Effects on growth of pathogenic bacteria and reepithelialization of superficial wounds. Arch Dermatol 1986; 122:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/98\">",
"      Fonder MA, Lazarus GS, Cowan DA, et al. Treating the chronic wound: A practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol 2008; 58:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/99\">",
"      Friedman SJ, Su WP. Management of leg ulcers with hydrocolloid occlusive dressing. Arch Dermatol 1984; 120:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/100\">",
"      Cordts PR, Hanrahan LM, Rodriguez AA, et al. A prospective, randomized trial of Unna's boot versus Duoderm CGF hydroactive dressing plus compression in the management of venous leg ulcers. J Vasc Surg 1992; 15:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/101\">",
"      Kikta MJ, Schuler JJ, Meyer JP, et al. A prospective, randomized trial of Unna's boots versus hydroactive dressing in the treatment of venous stasis ulcers. J Vasc Surg 1988; 7:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/102\">",
"      Arnold TE, Stanley JC, Fellows EP, et al. Prospective, multicenter study of managing lower extremity venous ulcers. Ann Vasc Surg 1994; 8:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/103\">",
"      Eriksson G. Comparison of two occlusive bandages in the treatment of venous leg ulcers. Br J Dermatol 1986; 114:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/104\">",
"      Leaper DJ. Silver dressings: their role in wound management. Int Wound J 2006; 3:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/105\">",
"      Burd A, Kwok CH, Hung SC, et al. A comparative study of the cytotoxicity of silver-based dressings in monolayer cell, tissue explant, and animal models. Wound Repair Regen 2007; 15:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/106\">",
"      Jones JE, Nelson EA. Skin grafting for venous leg ulcers. Cochrane Database Syst Rev 2005; :CD001737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/107\">",
"      Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 1999; 7:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/108\">",
"      Marston WA. Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer. Expert Rev Med Devices 2004; 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/109\">",
"      Park CA, Defranzo AJ, Marks MW, Molnar JA. Outpatient reconstruction using integra* and subatmospheric pressure. Ann Plast Surg 2009; 62:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/110\">",
"      Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol 1998; 134:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/111\">",
"      Shai A, Halevy S. Direct triggers for ulceration in patients with venous insufficiency. Int J Dermatol 2005; 44:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/112\">",
"      Kulozik M, Powell SM, Cherry G, Ryan TJ. Contact sensitivity in community-based leg ulcer patients. Clin Exp Dermatol 1988; 13:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/113\">",
"      Smack DP, Harrington AC, Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. JAMA 1996; 276:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/114\">",
"      Kaye ET, Kaye KM. Topical antibacterial agents. Infect Dis Clin North Am 1995; 9:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/115\">",
"      Blair, SD, Backhouse, CM, Wright, DD, et al. Do dressings influence the healing of chronic venous ulcers? Phlebology 1988; 3:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/116\">",
"      Wilkinson SM, English JS. Hydrocortisone sensitivity: clinical features of fifty-nine cases. J Am Acad Dermatol 1992; 27:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/117\">",
"      Wilkinson SM. Hypersensitivity to topical corticosteroids. Clin Exp Dermatol 1994; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/118\">",
"      Weingarten MS. State-of-the-art treatment of chronic venous disease. Clin Infect Dis 2001; 32:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/41/32410/abstract/119\">",
"      O'Donnell TF Jr. The present status of surgery of the superficial venous system in the management of venous ulcer and the evidence for the role of perforator interruption. J Vasc Surg 2008; 48:1044.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8270 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-C811B88612-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32410=[""].join("\n");
var outline_f31_41_32410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Leg elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONTINUOUS COMPRESSION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527637549\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709635695\">",
"      Compression bandages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Graduated compression stockings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Compression stocking prescription",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Use and care of compression stockings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Compliance with compression therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INTERMITTENT PNEUMATIC COMPRESSION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SYSTEMIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Systemic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pentoxifylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Stanozolol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Escin (horse chestnut seed extract)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hydroxyethylrutoside",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Sulodexide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prostacyclin analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SKIN CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Skin Cleansing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Emollients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Barrier preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ULCER CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Ulcer debridement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Ulcer dressings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Skin grafting and human skin equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      CONTACT DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      ULCER HEALING AND RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      COST OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8270\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8270|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?35/19/36159\" title=\"algorithm 1\">",
"      Treatment of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8270|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/58/26528\" title=\"figure 1\">",
"      Heel pocket out method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/50/13088\" title=\"figure 2\">",
"      Stocking donner",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8270|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/14/11490\" title=\"picture 1\">",
"      Stasis dermatitis sclerotic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8270|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/42/37547\" title=\"table 1\">",
"      Compression stockings in chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 2\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/53/32604\" title=\"table 3\">",
"      Properties of dressings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/60/12236\" title=\"table 4\">",
"      Representative costs to treat venous disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/29/11735?source=related_link\">",
"      Classification of lower extremity chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/40/19078?source=related_link\">",
"      Clinical assessment of wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13592?source=related_link\">",
"      Clinical evaluation of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/55/9079?source=related_link\">",
"      Compression bandaging for chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/43/33462?source=related_link\">",
"      Diagnostic evaluation of chronic venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30503?source=related_link\">",
"      General principles of the treatment of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34521?source=related_link\">",
"      Overview and management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/22/43365?source=related_link\">",
"      Pathophysiology of chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/17/35091?source=related_link\">",
"      Patient information: Chronic venous disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/47/41714?source=related_link\">",
"      Patient information: Varicose veins and other vein disease in the legs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37064?source=related_link\">",
"      Treatment of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_41_32411="Clinical group rhabdomyosarcoma";
var content_f31_41_32411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical grouping of rhabdomyosarcoma by the intergroup rhabdomyosarcoma study group (IRSG)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Extent of disease/surgical result",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        I",
"       </td>",
"       <td>",
"        A Localized tumor, confined to site of origin, completely resected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B Localized tumor, infiltrating beyond site of origin, completely resected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        II",
"       </td>",
"       <td>",
"        A Localized tumor, gross total resection, but with microscopic residual disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B Locally extensive tumor (spread to regional lymph nodes), completely resected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C Locally extensive tumor (spread to regional lymph nodes), gross total resection, but microscopic residual disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        III",
"       </td>",
"       <td>",
"        A Localized or locally extensive tumor, gross residual disease after biopsy only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B Localized or locally extensive tumor, gross residual disease after major resection (&ge;50 percent&nbsp;debulking)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Any size primary tumor, with or without regional lymph node involvement, with distant metastases, irrespective of surgical approach to primary tumor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13:610; and Crist W, Garnsey L, Beltangady M, et al. Prognosis in children with rhabdomyosarcoma: A report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee. J Clin Oncol 1990; 8:443.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32411=[""].join("\n");
var outline_f31_41_32411=null;
var title_f31_41_32412="Ingredient label terms for peanut";
var content_f31_41_32412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    How to read an ingredient label for a peanut-free diet",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Avoid foods that contain peanuts or any of these ingredients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artificial nuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beer nuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold pressed, expeller pressed, or extruded peanut oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goobers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ground nuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed nuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monkey nuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nut meat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nut pieces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peanut butter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peanut flour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peanut protein hydrolysate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Peanut is sometimes found in the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        African, Asian (especially Chinese, Indian, Indonesian, Thai, and Vietnamese), and Mexican dishes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baked goods (eg, pastries, cookies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candy (including chocolate candy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chili",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Egg rolls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enchilada sauce",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marzipan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mole sauce",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nougat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Keep the following in mind:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Mandelonas are peanuts soaked in almond flavoring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;",
"        <strong>",
"         The FDA exempts highly refined peanut oil from being labeled as an allergen.",
"        </strong>",
"        Studies show that most allergic individuals can safely eat peanut oil that has been highly refined (not cold pressed, expeller pressed, or extruded peanut oil). Follow your doctor's advice.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A study showed that unlike other legumes, there is a strong possibility of cross-reaction between peanuts and lupine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Arachis oil is peanut oil.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Many experts advise patients allergic to peanuts to avoid tree nuts as well.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Sunflower seeds are often produced on equipment shared with peanuts.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All FDA-regulated manufactured food products that contain peanut as an ingredient are required by US law to list the word \"peanut\" on the product label.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2010 The Food Allergy &amp; Anaphylaxis Network. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32412=[""].join("\n");
var outline_f31_41_32412=null;
var title_f31_41_32413="Course uncomplicated URI";
var content_f31_41_32413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Course of uncomplicated viral upper respiratory infection (URI)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 283px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The course of most uncomplicated viral URIs is 5 to 10 days. Most patients with viral URI are afebrile. If fever is present, it tends to occur on the first two days of illness, in concert with constitutional symptoms (eg, headache, myalgia). As fever and/or constitutional symptoms resolve, respiratory symptoms become more prominent, peaking in severity on days three to six of illness. Respiratory symptoms may continue to be present on day 10 of illness, but are less severe than earlier in the course.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32413=[""].join("\n");
var outline_f31_41_32413=null;
var title_f31_41_32414="FOLFIRI plus bevacizumab";
var content_f31_41_32414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    FOLFIRI plus bevacizumab chemotherapy for metastatic colorectal cancer",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bevacizumab",
"        </strong>",
"       </td>",
"       <td>",
"        5 mg/kg IV",
"       </td>",
"       <td>",
"        Dilute into a total volume of 100 mL normal saline (NS)*. The first dose should be administered over 90 minutes following chemotherapy. If well tolerated, the second infusion may be administered over 60 minutes after irinotecan and leucovorin. If well tolerated, all subsequent doses may be administered over 10 to 30 minutes before chemotherapy",
"        <sup>",
"         &Delta;[3,4]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Irinotecan",
"        </strong>",
"       </td>",
"       <td>",
"        180",
"        <sup>",
"         &loz;",
"        </sup>",
"        mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 mL 5 percent dextrose in water (D5W) and administer over 90 minutes (can be administered concurrently with leucovorin via y-site connection).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL D5W and administer over two hours.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Slow intravenous push over five minutes (administer immediately after leucovorin).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         FU",
"        </strong>",
"       </td>",
"       <td>",
"        2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 mL to 1000 mL D5W and administer over 46 hours. To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen for prophylaxis of infusion reactions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia approximately 5 percent",
"        <sup>",
"         [2]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of FU and irinotecan may be needed for patients with liver impairment. A lower starting dose of irinotecan may be needed for patients with severe renal impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Obtain CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in blood pressure, urine protein concentration, and risk for bleeding prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Each treatment should be delayed until absolute neutrophil count is &gt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and the platelet count is &gt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . US FDA-approved manufacturer's package insert suggests irinotecan dose reduction for grade 3 or worse hematologic toxicity (including febrile neutropenia) during treatment",
"        <sup>",
"         [5]",
"        </sup>",
"        . A different approach is used by some clinicians. If treatment is delayed for two weeks or delayed for one week on two separate occasions, the day 1 FU bolus is eliminated. With the second occurrence, reduce the FU infusion dose by 20 percent and reduce irinotecan dose to 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withhold treatment until resolution of diarrhea for at least 24 hours off all antidiarrheal medications. The US FDA-approved manufacturer's package insert suggests decreasing the irinotecan dose for patients with grade 2 or higher diarrhea in the prior cycle",
"        <sup>",
"         [5]",
"        </sup>",
"        . Withhold FU for grade 2 or worse diarrhea and restart at a lower dose after complete resolution",
"        <sup>",
"         [6]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        For other non-hematologic toxicities, hold treatment until less than or equal to grade 1, if grade 2; hold treatment until less than or equal to grade 2, if grade 3 or 4. The US FDA-approved manufacturer's package insert suggests decreasing the irinotecan dose for patients with grade 3 or higher non-hematologic toxicity other than diarrhea in the prior cycle. Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS)",
"        <sup>",
"         [3]",
"        </sup>",
"        . Bevacizumab should not be administered within 28 days of surgery, and it should be suspended prior to elective surgery. Refer to UpToDate topics on \"",
"        <span class=\"emphasis\">",
"         Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\" and \"",
"         <span class=\"emphasis\">",
"          Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"         </span>",
"         \"",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     &Delta; For the 5 mg/kg dose, many clinicians administer the first dose over 60 minutes and if well tolerated, subsequent doses are administered over 10 minutes",
"     <sup>",
"      [4]",
"     </sup>",
"     .",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     A lower initial starting dose of irinotecan is recommended for age &ge;65, poor performance status, prior pelvic or abdominal radiotherapy, or elevated bilirubin. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"     <br/>",
"     &sect; Leucovorin dose is given for d,l-racemic mixture",
"     <sup>",
"      [7]",
"     </sup>",
"     . Use half the dose for LEVOleucovorin (l-leucovorin).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Tournigand C, et al. J Clin Oncol 2004; 22:229.",
"      </li>",
"      <li>",
"       Fuchs CS, et al. J Clin Oncol 2007; 25:4779.",
"      </li>",
"      <li>",
"       Avastin (bevacizumab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2011).",
"      </li>",
"      <li>",
"       Reidy DL, et al. J Clin Oncol 2007; 25:2691.",
"      </li>",
"      <li>",
"       Camptosar (irinotecan hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2011).",
"      </li>",
"      <li>",
"       Leucovorin calcium injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32414=[""].join("\n");
var outline_f31_41_32414=null;
var title_f31_41_32415="Finger volar splint";
var content_f31_41_32415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Finger volar splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_41_32415=[""].join("\n");
var outline_f31_41_32415=null;
